1	Cholinergic and lipid mediators crosstalk in Covid-19 and the impact of
2	glucocorticoid therapy
3	*Malena M. Pérez, Ph.D. <sup>1</sup> ; *Vinícius E. Pimentel, B.Sc. <sup>1,7</sup> ; *Carlos A. Fuzo, Ph.D. <sup>1,8</sup>
4	*Pedro V. da Silva-Neto, M.Sc. <sup>1,8,9</sup> ; Diana M. Toro, M.Sc. <sup>1,8,9</sup> ; Camila O. S. Souza,
5	M.Sc. <sup>1,7</sup> ; Thais F. C. Fraga-Silva, Ph.D. <sup>2,7</sup> ; Luiz Gustavo Gardinassi, Ph.D. <sup>12</sup> ; Jonatan C.
6	S. de Carvalho <sup>1,5</sup> ; Nicola T. Neto <sup>1,10</sup> ; Ingryd Carmona-Garcia <sup>1,5</sup> ; Camilla N. S. Oliveira,
7	B.Sc. <sup>1,7</sup> ; Cristiane M. Milanezi, B.Sc. <sup>2</sup> Viviani Nardini Takahashi, Ph.D. <sup>1</sup> ; Thais Canassa
8	De Leo, M.Sc. <sup>1,8</sup> ; Lilian C. Rodrigues, Ph.D. <sup>1</sup> ; Cassia F. S. L. Dias, B.Sc. <sup>1,8</sup> ; Ana C.
9	Xavier <sup>10</sup> ; Giovanna S. Porcel <sup>10</sup> ; Isabelle C. Guarneri <sup>10</sup> ; Kamila Zaparoli <sup>11</sup> ; Caroline T.
10	Garbato <sup>11</sup> ; Jamille G. M. Argolo, M. Sc <sup>11</sup> ; Ângelo A. F. Júnior, M.Sc. <sup>11</sup> ; Marley R.
11	Feitosa, M.D. <sup>3,14</sup> ; Rogerio S. Parra, M.D. <sup>3,14</sup> ; José J. R. da Rocha, M.D. <sup>3</sup> ; Omar Feres,
12	M.D. <sup>3,14</sup> ; Fernando C. Vilar, M.D. <sup>4,14</sup> ; Gilberto G. Gaspar, M.D. <sup>4</sup> ; Rafael C. da Silva,
13	B.Sc. <sup>13</sup> ; Leticia F. Constant, B.M. <sup>13</sup> ; Fátima M. Ostini, B.M. <sup>13</sup> ; Alessandro P. de Amorim,
14	M.Sc. <sup>13</sup> ; Augusto M. Degiovani, B.M. <sup>13</sup> ; Dayane P. da Silva <sup>13</sup> , B.Sc.; Debora C.
15	Nepomuceno, B.Sc.N. <sup>13</sup> ; Rita C. C. Barbieri, B.Sc.N. <sup>14</sup> ; Isabel K. F. M. Santos, Ph.D. <sup>2</sup> ;
16	Sandra R. C. Maruyama, Ph.D. <sup>6</sup> ; Elisa M. S. Russo, Ph.D. <sup>1</sup> ; Angelina L. Viana, Ph.D. <sup>10</sup> ;
17	Ana P. M. Fernandes, Ph.D. <sup>11</sup> ; Vânia L. D. Bonato, Ph.D. <sup>2,7</sup> ; Cristina R. B. Cardoso,
18	Ph.D. <sup>1,7</sup> <sup>†</sup> ; Carlos A. Sorgi, Ph.D. <sup>5,9</sup> <sup>†</sup> ; Marcelo Dias-Baruffi, Ph.D. <sup>1,8</sup> <sup>†</sup> ; and Lúcia H.
19	Faccioli, Ph.D. <sup>1,7</sup> †§
20	
21	*Equal contribution: Malena Martínez Pérez, Ph.D.; Vinícius Eduardo Pimentel, B. Sc;

- 22 Carlos A. Fuzo, Ph.D. and Pedro Vieira da Silva-Neto, M.Sc.
- 23 **†Senior authors with equal contribution**: Cristina R. B. Cardoso, Ph.D.; Carlos A.
- 24 Sorgi, Ph.D.; Marcelo Dias-Baruffi; Ph.D. and Lúcia Helena Faccioli, Ph.D.
- 25 NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

26	§Corresponding author: Lúcia Helena Faccioli, Ph.D. ( <u>faccioli@fcfrp.usp.br</u> )
27	Departamento de Análises Clínicas, Toxicológicas e Bromatológicas. Faculdade de
28	Ciências Farmacêuticas de Ribeirão Preto - FCFRP, Universidade de São Paulo - USP
29	Av. do Café, s/n - Vila Monte Alegre, Ribeirão Preto - SP, 14040-900, Ribeirão Preto,
30	São Paulo, Brazil. FCFRP-USP, Bloco S, Sala 96A.
31	
32	1 - Departamento de Análises Clínicas, Toxicológicas e Bromatológicas. Faculdade de
33	Ciências Farmacêuticas de Ribeirão Preto - FCFRP, Universidade de São Paulo - USP,
34	Ribeirão Preto, São Paulo, Brazil;
35	2 - Departamento de Bioquímica e Imunologia. Faculdade de Medicina de Ribeirão Preto
36	- FMRP, Universidade de São Paulo-USP, São Paulo, Brazil;
37	3 - Departamento de Cirurgia e Anatomia, Faculdade de Medicina de Ribeirão Preto -
38	FMRP, Universidade de São Paulo-USP, Ribeirão Preto, São Paulo, Brazil;
39	4 - Departamento de Clínica Médica, Faculdade de Medicina de Ribeirão Preto - FMRP,
40	Universidade de São Paulo-USP, São Paulo, Brazil;
41	5 - Departamento de Química. Faculdade de Filosofia, Ciências e Letras de Ribeirão Preto
42	- FFCLRP. Universidade de São Paulo-USP, Ribeirão Preto, São Paulo, Brazil;
43	6 - Departamento de Genética e Evolução, Centro de Ciências Biológicas e da Saúde
44	Universidade Federal de São Carlos - UFSCar, São Carlos, São Paulo, Brazil;
45	7 - Programa de Pós-graduação em Imunologia Básica e Aplicada, Faculdade de Medicina
46	de Ribeirão Preto - FMRP, Universidade de São Paulo-USP, Ribeirão Preto São Paulo,
47	Brazil;

48	8 - Programa de Pós-graduação em Biociências e Biotecnologia Aplicadas à Farmácia,
49	Faculdade de Ciências Farmacêuticas de Ribeirão Preto - FCFRP, Universidade de São
50	Paulo - USP, Ribeirão Preto, São Paulo, Brazil;
51	9 - Programa de Pós-graduação em Imunologia Básica e Aplicada, Instituto de Ciências
52	Biológicas, Universidade Federal do Amazonas - UFAM, Manaus, Amazonas, Brazil;
53	10 - Departamento de Enfermagem Materno-Infantil e Saúde Pública, Escola de
54	Enfermagem de Ribeirão Preto - EERP, Universidade de São Paulo-USP, Ribeirão Preto,
55	São Paulo, Brazil;
56	11 - Departamento de Enfermagem Geral e Especializada, Escola de Enfermagem de
57	Ribeirão Preto - EERP, Universidade de São Paulo-USP, Ribeirão Preto, São Paulo,
58	Brazil;
50	12 Instituto de Detelogie Tropicel e Seúde Dúblice, Universidade Federal de Goiés

59 12 - Instituto de Patología Tropical e Saúde Pública, Universidade Federal de Goiás 60 UFG, Goiânia, Goiás, Brazil;

61 13 - Hospital Santa Casa de Misericórdia de Ribeirão Preto, Ribeirão Preto, São Paulo,
62 Brazil;

63 14 - Hospital São Paulo, Ribeirão Preto, São Paulo, Brazil.

### 64 Abstract

65 Cytokine storms and hyperinflammation, potentially controlled by glucocorticoids, occur 66 in COVID-19; the roles of lipid mediators and acetylcholine (ACh) and how 67 glucocorticoid therapy affects their release in Covid-19 remain unclear. Blood and 68 bronchoalveolar lavage (BAL) samples from SARS-CoV-2- and non-SARS-CoV-2-69 infected subjects were collected for metabolomic/lipidomic, cytokines, soluble CD14 70 (sCD14), and ACh, and CD14 and CD36-expressing monocyte/macrophage 71 subpopulation analyses. Transcriptome reanalysis of pulmonary biopsies was performed 72 by assessing coexpression, differential expression, and biological networks. Correlations 73 of lipid mediators, sCD14, and ACh with glucocorticoid treatment were evaluated. This 74 study enrolled 190 participants with Covid-19 at different disease stages, 13 hospitalized 75 non-Covid-19 patients, and 39 healthy-participants. SARS-CoV-2 infection increased 76 blood levels of arachidonic acid (AA), 5-HETE, 11-HETE, sCD14, and ACh but 77 decreased monocyte CD14 and CD36 expression. 5-HETE, 11-HETE, cytokines, ACh, 78 and neutrophils were higher in BAL than in circulation (fold-change for 5-HETE 389.0; 79 11-HETE 13.6; ACh 18.7, neutrophil 177.5, respectively). Only AA was higher in 80 circulation than in BAL samples (fold-change 7.7). Results were considered significant 81 at P<0.05, 95%CI. Transcriptome data revealed a unique gene expression profile 82 associated with AA, 5-HETE, 11-HETE, ACh, and their receptors in Covid-19. 83 Glucocorticoid treatment in severe/critical cases lowered ACh without impacting disease 84 outcome. We first report that pulmonary inflammation and the worst outcomes in Covid-85 19 are associated with high levels of ACh and lipid mediators. Glucocorticoid therapy 86 only reduced ACh, and we suggest that treatment may be started early, in combination 87 with AA metabolism inhibitors, to better benefit severe/critical patients.

# 88 Introduction

Individuals Covid-19 may present asymptomatically or with manifestations ranging from acute respiratory distress syndrome to systemic hyperinflammation and organ failure, events attributed to cytokine storms<sup>1</sup>. Free polyunsaturated fatty acids, such as AA and derivative eicosanoids, regulate inflammation<sup>2,3</sup>, yet their role in Covid-19 has not been well investigated.

ACh, which is released by nerves<sup>4</sup>, leukocytes<sup>5</sup>, and airway epithelial cells<sup>6</sup>, regulates metabolism<sup>7</sup>, cardiac function<sup>8</sup>, airway inflammation<sup>9</sup>, and cytokine production<sup>10</sup>, all of which occur in Covid-19. It is known that eicosanoids stimulate ACh release<sup>3</sup>, but crosstalk between cholinergic and lipid mediator pathways in Covid-19 still need to be clarified.

In this study, levels of lipid mediators, ACh, and other inflammatory markers in
blood and BAL from patients with Covid-19 who were treated or not with glucocorticoids
were compared to those of non-Covid-19 and healthy-participants. Moreover, lung biopsy
transcriptome reanalysis data from Covid-19 and non-Covid-19 patients corroborated our
findings.

104 Methods

### 105 Study design and blood collection

This observational, analytic, and transversal study was conducted from June to November 2020. All participants were over 16 years old and chosen according to the inclusion and exclusion criteria described in Table S1 and in the protocol, after providing signed consent. Blood samples collected from patients positive for Covid-19 (n=190) were analyzed by RT-qPCR (Biomol OneStep/Covid-19 kit; Institute of Molecular Biology of Paraná - IBMP Curitiba/PR, Brazil) using nasopharyngeal swabs and/or

serological assays to detect IgM/IgG/IgA (SARS-CoV-2<sup>®</sup> antibody test; Guangzhou 112 113 Wondfo Biotech, China). Samples obtained from a cohort of SARS-CoV-2-negative 114 healthy participants were used as controls (n=39). Participants positive for Covid-19 were 115 categorised as asymptomatic-mild (n=43), moderate (n=44), severe (n=54), or critical 116 (n=49). The criteria for the clinical classification of patients were defined at the time of 117 sample collection, as shown in Table S1. Peripheral blood samples were obtained by 118 venous puncture from patients upon their first admission and/or during the period of 119 hospitalisation at two medical centres, Santa Casa de Misericordia de Ribeirão Preto and 120 Hospital Sao Paulo at Ribeirão Preto, São Paulo State, Brazil. Blood samples from 121 healthy controls and asymptomatic-mild non-hospitalized participants were collected 122 either at the Centre of Scientific and Technological Development "Supera Park" 123 (Ribeirão Preto, São Paulo State, Brazil) or in the home of patients receiving at-home 124 care. The plasma was separated from whole blood samples and stored at -80°C. For 125 lipidomic and metabolomic analyses, 250 µL of plasma was stored immediately in 126 methanol (1:1 v/v). Lipidomic and metabolomic analyses were performed by mass 127 spectrometry (LC-MS/MS), while a cytokines, sCD14, and ACh were quantified using 128 CBA flex Kit (flow cytometer assay) or commercial ELISA. The expression levels of 129 CD14, CD36, CD16, and HLA-DR in cells were evaluated by flow cytometry following 130 the gate strategy (Figure S2).

## 131 Ethical considerations

All participants provided written consent in accordance with the regulations of the Conselho Nacional de Pesquisa em Humanos (CONEP) and the Human Ethical Committee from Faculdade de Ciências Farmacêuticas de Ribeirão Preto (CEP-FCFRP-USP). The research protocol was approved and received the certificate of Presentation and Ethical Appreciation (CAAE: 30525920.7.0000.5403). The sample size was Page 6 of 84

determined by the convenience of sampling, availability at partner hospitals, agreement
to participate, and the pandemic conditions within the local community (more information
in the Protocol).

## 140 Bronchoalveolar lavage fluid (BAL) collection and processing

141 BAL fluids were collected from hospitalised Covid-19 patients at the severe or critical 142 stages of disease (n=32) to assess their lung immune responses. Control samples were 143 obtained from hospitalised intubated donors negative for SARS-CoV-2 (n=13) (as 144 certified by SARS-CoV-2-negative PCR), referred to as non-Covid-19 patients, who were 145 intubated because of the following primary conditions: bacterial pneumonia, abdominal 146 septic shock associated with respiratory distress syndrome, pulmonary atelectasis due to 147 phrenic nerve damage, or pulmonary tuberculosis. BAL fluid was collected as previously 148 described<sup>11</sup>, using a siliconized polyvinylchloride catheter (Mark Med, Porto Alegre, 149 Brazil) with a closed Trach Care endotracheal suction system (Bioteque Corporation, 150 Chirurgic Fernandes Ltd., Santana Parnaíba, Brazil) and sterile 120 mL polypropylene 151 flask (Biomeg-Biotec Hospital Products Ltd., Mairiporã, Brazil) under aseptic conditions. 152 Approximately 5–10 mL of bronchoalveolar fluid was obtained and placed on ice for 153 processing within 4 h. The BAL fluids were placed into 15-mL polypropylene collection 154 tubes and received half volume of their volume of phosphate buffered saline (PBS) 0.1 M (2:1 v/v) in relation to the total volume of each sample. After centrifugation (700  $\times g$ , 155 156 10 min), the supernatants of the BAL fluid were recovered and stored at -80°C. For 157 lipidomic and metabolomic analyses, 250 µL of these supernatants were stored 158 immediately in methanol (1:1  $\nu/\nu$ ). Subsequently, the remaining BAL fluid was diluted in 159 10 mL of PBS and gently filtered through a 100-um cell strainer (Costar, Corning, NY, 160 USA) using a syringe plunger. The resulting material was used for cytokine and 161 acetylcholine (ACh) quantification. The BAL fluids were centrifuged ( $700 \times g$ , 10 min) Page 7 of 84

162 and the red blood cells were lysed using 1 mL of ammonium chloride (NH<sub>4</sub>Cl) buffer 163 0.16 M for 5 min. The remaining airway cells were washed with 10 mL of PBS, 164 resuspended in PBS-2% heat-inactivated foetal calf serum, and counted with Trypan blue 165 using an automated cell counter (Countess, Thermo Fisher Scientific, Waltham, MA, 166 USA). The leukocyte numbers were adjusted to  $1 \times 10^9$  cells/L for differential counts and  $1 \times 10^{6}$  cells/mL for flow cytometry analysis. All procedures were performed in a Level 167 168 3 Biosafety Facility (Departamento de Bioquímica e Imunologia, Faculdade de Medicina 169 de Ribeirão Preto, Universidade de São Paulo).

## 170 Data collection

171 The electronic medical records of each patient were carefully reviewed. Data 172 included sociodemographic information, comorbidities, medical history, clinical 173 symptoms, routine laboratory tests, immunological tests, chest computed tomography 174 (CT) scans, clinical interventions, and outcomes (more information in the Protocol). The 175 information was documented on a standardised record form, as indicated in Tables S1, 176 S2, and S3. Data collection of laboratory results included first-time examinations within 177 24 h of admission, defined as the primary endpoint. The secondary endpoint was clinical 178 outcome (death or recovery).

#### 179 Clinical laboratory collection

For hospitalised patients, blood examinations were performed by clinical analysis laboratories at their respective hospitals. Blood examinations of healthy participants and non-hospitalized patients were performed at *Serviço de Análises Clínicas* (SAC), *Departamento de Análises Clínicas, Toxicológicas e Bromatológicas* of the *Faculdade de Ciências Farmacêuticas de Ribeirão Preto, Universidade de São Paulo, Ribeirão* 

185 Preto, São Paulo, Brazil. The blood samples were used to measure for liver and kidney 186 function, myocardial enzyme spectrum, coagulation factors, red blood cells, 187 haemoglobin, platelets, and total and differential leukocytes using automated equipment. 188 Similarly, the absolute numbers of leukocytes in the BAL fluid were determined in a 189 Neubauer Chamber with Turkey solution. For the counts of differential leukocytes in the 190 BAL, 100 µL of the fluid was added to cytospin immediately after collection to avoid any 191 interference on cell morphology. Differential leukocyte counts were conducted using an 192 average of 200 cells after staining with Fast Panoptic (LABORCLIN; Laboratory 193 Products Ltd, Pinhais, Brazil) and examined under an optical microscope (Zeiss EM109; 194 Carl Zeiss AG, Oberkochen, Germany) with a 100× objective (immersion oil) equipped 195 with a Veleta CCD digital camera (Olympus Soft Imaging Solutions Gmbh, Germany) 196 and ImageJ (1.45s) (National Institutes of Health, Rockville, MD, USA)<sup>12</sup>. Lymphocytes, 197 neutrophils, eosinophils, and monocytes/macrophages identified were and 198 morphologically characterised, and their lengths and widths were measured  $(100\times)$ .

# High-performance liquid chromatography coupled with tandem Mass Spectrometry (LC-MS/MS) assay

### 201 Reagents

Eicosanoids, free fatty acids (AA, EPA, and DHA), and metabolites as molecular weight standards (MWS) and deuterated internal standards were purchased from Cayman Chemical Co. (Ann Arbor, MI, USA). HPLC-grade acetonitrile (ACN), methanol (MeOH), and isopropanol were purchased from Merck (Kenilworth, NJ, USA). Ultrapure deionised water (H<sub>2</sub>O) was obtained using a Milli-Q water purification system (Merck-Millipore, Kenilworth, NJ, USA). Acetic acid (CH<sub>3</sub>COOH) and ammonium hydroxide (NH<sub>4</sub>OH) were obtained from Sigma Aldrich (St. Louis, MO, USA).

#### 209 Sample preparation and extraction

The plasma (250 µL) in EDTA-containing tubes (Vacutainer<sup>®</sup> EDTA K2; BD 210 211 Diagnostics, Franklin Lakes, NJ, USA) and BAL (250 µL) samples were stored in MeOH 212 (1:1, v/v) at  $-80^{\circ}$ C. Three additional volumes of ice-cold absolute MeOH were added to 213 each sample overnight at -20°C for protein denaturation and after lipid solid-phase 214 extraction (SPE). To each sample, 10  $\mu$ L of internal standard (IS) solution was added, 215 centrifuged at 800  $\times$  g for 10 min at 4°C. The resulting supernatants were collected and 216 diluted with deionised water (ultrapure water; Merck-Millipore, Kenilworth, NJ, USA) to 217 obtain a MeOH concentration of 10% (v/v). In the SPE extractions, a Hypersep C18-500 218 mg column (3 mL) (Thermo Scientific-Bellefonte, PA, USA) equipped with an extraction 219 manifold collector (Waters-Milford, MA, USA) was used. The diluted samples were 220 loaded into the pre-equilibrated column and washing using 2 mL of MeOH and  $H_2O$ 221 containing 0.1% acetic acid, respectively. Then, the cartridges were flushed with 4 mL of 222 H<sub>2</sub>O containing 0.1% acetic acid to remove hydrophilic impurities. The lipids that had 223 been adsorbed on the SPE sorbent were eluted with 1 mL of MeOH containing 0.1% 224 acetic acid. The eluates solvent was removed in vacuum (Concentrator Plus, Eppendorf, 225 Germany) at room temperature and reconstituted in 50  $\mu$ L of MeOH/H2O (7:3,  $\nu/\nu$ ) for 226 LC-MS/MS analysis.

#### 227 LC-MS/MS analysis and lipids data processing

Liquid chromatography was performed using an Ascentis Express C18 column (Supelco, St. Louis, MO, USA) with  $100 \times 4.6$  mm and a particle size of 2.7 µm in a highperformance liquid chromatography (HPLC) system (Nexera X2; Shimadzu, Kyoto, Japan). Then, 20 µL of extracted sample was injected into the HPLC column. Elution was carried out under a binary gradient system consisting of Phase A, comprised of H<sub>2</sub>O,

233 ACN, and acetic acid (69.98:30:0.02, v/v/v) at pH 5.8 (adjusted with NH<sub>4</sub>OH), and Phase 234 B, comprised of ACN and isopropanol (70:30, v/v). Gradient elution was performed for 235 25 min at a flow rate of 0.5 mL/min. The gradient conditions were as follows: 0 to 2 min, 236 0% B; 2 to 5 min, 15% B; 5 to 8 min, 20% B; 8 to 11 min, 35% B; 11 to 15 min, 70% B; 237 and 15 to 19 min, 100% B. At 19 min, the gradient was returned to the initial condition 238 of 0% B, and the column was re-equilibrated until 25 min. During analysis, the column 239 samples were maintained at 25°C and 4°C in the auto-sampler. The HPLC system was 240 directly connected to a TripleTOF 5600+ mass spectrometer (SCIEX-Foster, CA, USA). 241 An electrospray ionisation source (ESI) in negative ion mode was used for high-resolution multiple-reaction monitoring (MRM<sup>HR</sup>) scanning. An atmospheric-pressure chemical 242 243 ionisation probe (APCI) was used for external calibrations of the calibrated delivery 244 system (CDS). Automatic mass calibration (<2 ppm) was performed periodically after 245 each of the five sample injections using APCI Negative Calibration Solution (Sciex-246 Foster, CA, USA) injected via direct infusion at a flow rate of 300 µL/min. Additional 247 instrumental parameters were as follows: nebuliser gas (GS1), 50 psi; turbo gas (GS2), 248 50 psi; curtain gas (CUR), 25 psi; electrospray voltage (ISVF), -4.0 kV; temperature of 249 the turbo ion spray source, 550°C. The dwell time was 10 ms, and a mass resolution of 250 35,000 was achieved at m/z 400. Data acquisition was performed using Analyst<sup>TM</sup> 251 software (SCIEX- Foster, CA, USA). Qualitative identification of the lipid species was performed using PeakView<sup>TM</sup> (SCIEX-Foster, CA, USA). MultiQuant<sup>TM</sup> (SCIEX-Foster, 252 253 CA, USA) was used for the quantitative analysis, which allows the normalisation of the 254 peak intensities of individual molecular ions using an internal standard for each class of 255 lipid. The quantification of each compound was performed using internal standards and 256 calibration curves, and the specific mass transitions of each lipid were determined

according to our previously published method<sup>13</sup>. The final concentration of lipids was
normalised by the initial volume of plasma or BAL fluid (ng/mL).

#### 259 Metabolomics analysis

260 Metabolite was extracted and samples were transferred to autosampler vials for 261 LC-MS analysis using TripleTOF5600+ Mass Spectrometer (Sciex-Foster, CA, USA) 262 coupled to an ultra-high-performance liquid chromatography (UHPLC) system (Nexera 263 X2; Shimadzu, Kyoto, Japan). Reverse-phase chromatography was performed similarly 264 to lipids analyses above. Mass spectral data were acquired with negative electrospray 265 ionisation, and the full scan of mass-to-charge ratio (m/z) ranged from 100 to 1500. Proteowizard software<sup>14</sup> was used to convert the wiff files into mz XML files. Peak 266 267 peaking, noise filtering, retention time, m/z alignment, and feature quantification were 268 performed using apLCMS<sup>15</sup>. Three parameters were used to define a metabolite feature: 269 mass-to-charge ratio (m/z), retention time (min), and intensity values. Data were  $\log_2$ 270 transformed and only features detected in at least 50% of samples from one group were 271 used in further analyses. Missing values were imputed using half the mean of the feature 272 across all samples. Mummichog (version 2) was used for metabolic pathway enrichment analysis (mass accuracy under 10 ppm)<sup>16</sup>. 273

# 274 Acetylcholine measurement

ACh was measured in heparinized plasma (SST<sup>®</sup> Gel Advance<sup>®</sup>; BD Diagnostics, Franklin Lakes, NJ, USA) and in BAL using a commercially available immunofluorescence kit (ab65345; Abcam, Cambridge, UK) according to the manufacturer's instructions. Briefly, ACh was converted to choline by adding the enzyme acetylcholinesterase to the reaction, which allows for total and free-choline measurement. The amount of ACh present in the samples was calculated by subtracting the free choline

from the total choline. The products formed in the assay react with the choline probe and can be measured by fluorescence with excitation and emission wavelengths of 535 and 587 nm, respectively (Paradigm Plate Reader; SpectraMax, San Diego, CA, USA). The concentration of ACh was analysed using SoftMax<sup>®</sup> software (SpectraMax, Molecular Devices, Sunnyvale, CA, USA), expressed as pmol.mL<sup>-1</sup>.

286 Soluble CD14 (sCD14) measurement

Samples from heparinized plasma (SST<sup>®</sup> Gel Advance<sup>®</sup>; BD Biosciences, Franklin
Lakes, NJ, USA) were placed in 96-well plates. The concentration of sCD14 was
determined using an ELISA kit (DY383; R&D Systems, Minneapolis, MN, USA),
following the manufacturer's instructions, expressed as pg.mL<sup>-1</sup>.

## 291 Flow Cytometry

Uncoagulated blood samples in EDTA-containing tubes (Vacutainer® EDTA K2; BD 292 293 Biosciences) were processed for flow cytometry analysis of circulating leukocytes. 294 Whole blood (1 mL) was separated and red blood cells were lysed using RBC lysis buffer 295 (Roche Diagnostics GmbH, Mannheim, GR). Leukocytes were washed in PBS containing 296 5% foetal bovine serum (FBS) (Gibco<sup>™</sup>, USA), centrifuged, and resuspended in Hank's 297 balanced salt solution (Sigma-Aldrich, Merck, Darmstadt, Germany) containing 5% FBS, 298 followed by surface antigen staining. Similarly, cells obtained from BAL fluid were 299 processed for flow cytometry assays. Briefly, cells were stained with Fixable Viability 300 Stain 620 (1:1000) (BD Biosciences) and incubated with monoclonal antibodies specific 301 for CD14 (1:100) (M5E2; Biolegend), HLA-DR (1:100) (G46-6; BD Biosciences), CD16 302 (1:100) (3G8; Biolegend), and CD36 (1:100) (CB38, BD Biosciences) for 30 min at 4°C. 303 Stained cells were washed and fixed with BD Cytofix<sup>™</sup> Fixation Buffer (554655; BD 304 Biosciences, San Diego, CA, USA). Data acquisition was performed using a LSR-

Fortessa<sup>TM</sup> flow cytometer (BD Biosciences, San Jose, CA, USA) and FACS-Diva
software (version 8.0.1) (BD Biosciences, Franklin Lakes, NJ, USA). For the analysis,
300,000 events were acquired for each sample. Data were evaluated using FlowJo<sup>®</sup>
software (version 10.7.0) (Tree Star, Ashland, OR, USA) to calculate the cell frequency,
dimensionality reduction, and visualisation using t-distributed stochastic neighbour
embedding. Gate strategy performed as described before <sup>17</sup>, as shown in Figure S2.

#### 311 Cytokine Measurements

312 The cytokines interleukin (IL)-6, IL-8, IL-16, IL-10, and tumour necrosis factor 313 (TNF) were quantified in heparinized plasma and BAL fluid samples using a BD 314 Cytometric Bead Array (CBA) Human Inflammatory Kit (BD Biosciences, San Jose, CA, 315 USA), according to manufacturer's instructions. Briefly, after sample processing, the 316 cytokine beads were counted using a flow cytometer (FACS Canto TM II; BD 317 Biosciences, San Diego, CA, USA), and analyses were performed using FCAP Array 318 (3.0) software (BD Biosciences, San Jose, CA, USA). The concentrations of cytokines 319 were expressed as  $pg.mL^{-1}$ .

#### 320 Re-analysis of transcriptome data from lung biopsies of patients with Covid-19

321 To gain a better understanding of the correlation between the altered concentrations 322 of ACh, AA, and AA-metabolites detected in the plasma and BAL fluid of severe/critical 323 Covid-19 patients, we performed a new analysis by re-using a previously published 324 transcriptome open dataset <sup>18</sup>, deposited in the Gene Expression Omnibus repository under accession no. GSE150316<sup>19</sup>. We used transcriptome data from lung samples 325 326 (n=46) from patients with Covid-19 (n=15), seven of which displayed a low viral load 327 and eight a high viral load, and non-Covid-19 patients (n=5) with other pulmonary 328 illnesses (negative control). Patients with a high viral load had meantime periods of

329 hospital stays ( $3.6\pm2.2$  days) and duration of illness ( $7.2\pm3.02$  days) shorter than the 330 patients with low viral load ( $14\pm7.9$  and  $19\pm4.9$  days, respectively), as described by the authors of the public data source <sup>18</sup>. Hence, for analysis purposes, all patient samples were 331 332 grouped into four classifications: Covid-19 (CV), Covid-19 low viral load (CVL), Covid-333 19 high viral load (CVH), and non-Covid-19 (NCV). The strategy for reanalysing the 334 transcriptome was implemented according to three consecutive steps: (i) co-expression 335 analysis, (ii) differential expression analysis, and (iii) biological network construction. 336 Initially, for the co-expression study, normalised transcriptome data in  $\log_2$  of reads per 337 million (RPM) were filtered by excluding non-zero counts in at least 20% of the samples. 338 Next, the selected genes were explored in the R package Co-Expression Modules identification Tool (CEMITool)<sup>20</sup>, using a *p*-value of 0.05 as the threshold for filtering. 339 340 Then, the co-expression modules were analysed for the occurrence of ACh and AA genes list obtained from the Reactome pathways<sup>21</sup>, as well as the Covid-19-related genes 341 342 obtained from the literature (Supplementary Appendix I). Next, differential gene 343 expression between samples from the lung biopsy transcriptome (CV, NCV, CVL, and 344 CVH) was measured using the DESeq2 package  $^{22}$ , with *p*-values adjusted using the Benjamini and Hochberg method <sup>23</sup>. The list of differentially express genes (DEGs) 345 346 generated for all comparisons was filtered from the genes listed in Supplementary 347 Appendix I, considering the values of  $\log_2$  of fold-change (FC) greater than 1 348  $(|\log_2(FC)|>1)$  and adjusted p<0.05. Finally, a first-order biological network was 349 constructed using co-expression module(s) containing genes associated with the ACh and 350 AA pathways to characterise the interplay between these mediators in combination with 351 Covid-19 severity markers, as well as to identify relevant DEGs and hub genes in this network, using the BioGRID repository <sup>24</sup>. The networks were constructed, analysed, and 352 graphically represented using the R packages igraph <sup>25</sup>, Intergraph <sup>26</sup>, and ggnetwork <sup>27</sup>. 353

Due to the substantial influence of glucocorticoid treatment on the levels of some mediators, we measured the sensitivity of genes from the differential expression analysis between CV samples from patients who underwent treatment (CTC, three patients and ten samples) and patients who were not treated (NCTC, 12 patients and 36 samples), as previously described <sup>18</sup>.

#### 359 Statistical Analysis

360 Two-tailed tests were used for the statistical analysis, with a significance value of p < 0.05 and a confidence interval of 95%. The data were evaluated for a normal 361 362 distribution using the Kolmogorov-Smirnov test. The parametric data were analysed 363 using unpaired t-tests (for two groups) or one-way ANOVA followed by Tukey's multiple 364 comparison tests for three or more groups simultaneously. For data that did not display a 365 Gaussian distribution, Mann-Whitney (for two-group comparisons) or Kruskal-Wallis 366 testes were used, followed by Dunn's post-tests for analysis among three or more groups. 367 The cytokine network data in patients with Covid-19 were analysed using significant 368 Spearman's correlations at p < 0.05. Data were represented by connecting edges to highlight positive strong ( $r \ge 0.68$ ; thick continuous line), moderate ( $0.36 \ge r < 0.68$ ; 369 thinner continuous line), or weak (0 > r < 0.36; thin continuous line) and negative strong 370 371  $(r \le -0.68;$  thick dashed line), moderate  $(-0.68 > r \le -0.36;$  thinner dashed line), or weak (-0.36 < r > 0); thin dashed line), as proposed previously <sup>28,29</sup>. The absence of a line 372 373 indicates the non-existence of the relationship. The Venn diagrams were elaborated using 374 the online tool Draw Venn Diagram (http://bioinformatics.psb.ugent.be/webtools/Venn/). 375 The results were tabulated using GraphPad Prism software (version 8.0) and the 376 differences were considered statistically significant at p < 0.05. See the Additional 377 Statistical Report section for more information. Some of the confounding variables associated with Covid-19 (age, sex, obesity, hypertension, and diabetes mellitus) were 378 Page 16 of 84

analysed for their potential impacts on the main analytical procedures of this study, such as ACh, AA, 5-HETE, and 11- HETE measurements of the plasma (healthy, asymptomatic-to-mild, moderate, severe, and critical patients) and BAL (severe and critical patients) samples. This analysis was performed using the Kruskal-Wallis, Mann-Whitney, Spearman's correlation, or Chi-square ( $\chi 2$ ) tests (Table S7-S9).

384 **Results** 

# 385 Study Population

This study enrolled 39 healthy-participants, 13 hospitalized non-Covid-19, and 190 Covid-19 patients aged 16-96 years from April to November 2020. The 190 Covid-19 patients were categorized as having asymptomatic-to-mild (n=43), moderate (n=44), severe (n=54), or critical (n=49) disease (Table S2).

# 390 Covid-19 Modifies Circulating Soluble Mediators and Cell Populations

391 To determine whether SARS-CoV-2 infection alters the metabolism of lipid 392 mediators, we used high-resolution sensitive mass spectrometry to perform targeted 393 eicosanoid analysis and nontargeted metabolomics using plasma from healthy-394 participants and Covid-19 patients. In total, 8,791 metabolite features were present in at 395 least 50% of all samples, and the relative abundance of 595 metabolite features (FDR 396 adjusted P<0.05) was altered in the groups studied (Figure 1A). Two-way hierarchical 397 clustering based on these significant metabolite features resulted in three clear clusters: one for severe/critical Covid-19 patients, one for healthy-participants and one for 398 399 asymptomatic-to-mild and moderate Covid-19 (Figure S1A). Pathway analysis revealed 400 the top significant metabolic pathways to be enriched in features involved in fatty acid 401 biosynthesis, metabolism, activation, and oxidation (Figure 1B). Compared to healthy-

402 participants, tentative metabolite annotations suggested an increased abundance of fatty 403 acids (FFAs), such as linoleic acid, tetradecanoate, dodecanoate and AA, in COVID-19 404 (Figure 4C-F). Among the identified lipids, AA was the most abundant, and its levels 405 correlated with the severity of Covid-19 (Figure 1F). Linoleic acid can be metabolized to 406 AA, which in turn is a substrate for eicosanoids, such as 5-hydroxyeicosatetraenoic acid 407 (5-HETE) and 11-hydroxyeicosatetraenoic acid (11-HETE) (Figure 1G, 1H); both 408 molecules with function in the immune response. Overall, the increased plasma levels of 409 AA in Covid-19 indicate that it predicts disease severity.

As eicosanoids induce cell recruitment and regulate immune responses, we next determined the profile of immune cells and soluble mediators in whole blood and plasma of patients with Covid-19 and healthy-participants. According to whole-blood analysis, absolute leukocyte and neutrophil counts (Figure 2A, 2B) were significantly higher but lymphocyte counts (Figure 2C) significantly lower in patients with severe/critical disease than in those with moderate disease. Eosinophil (Figure 2D) and basophil counts (Figure 2E) were reduced severe disease compared to asymptomatic and moderate disease.

417 Although no differences in total monocyte counts among the groups (Figure 2F) 418 were observed based on CD16, CD14 and HLA-DR, expression of membrane CD14 was reduced in all SARS-CoV-2-infected patients compared to healthy-participants (Figure 419 420 2G; Figure S2, S3). In parallel, CD36 expression was decreased in monocytes from 421 patients with severe/critical disease (Figure 2H), but sCD14 was increased only in plasma 422 from critical patients (Figure 2I). We did not detect differences in classic or non-classic 423 monocytes, but the percentage of intermediate monocytes was decreased in all SARS-424 CoV-2-infected participants compared to healthy-participants (Figure 2J, 2K, 2L). Based 425 on plasma cytokine level analysis, patients with moderate, severe, and critical disease

share a Covid-19 cytokine profile defined by increased IL-8, IL-6, and IL-10 (Figure 2M,
2N, 2Q) levels, with unaltered IL-1β and TNF levels (Figure 2O, 2P).

428

#### 8 Covid-19 Induces Strong Lung Responses

429 We performed measurements of BAL from hospitalized Covid-19 and non-430 Covid-19 patients. Changes in lung metabolomics induced by SARS-CoV-2 infection 431 (Figure 3A; Figure S1B) included alterations in sphingolipids, beta oxidation of 432 trihydroxyprostanoil-CoA, biosynthesis and metabolism of steroidal hormones, vitamin 433 D3, and glycerophospholipids (Figure 3B). We also evaluated AA and its metabolites. 434 Despite no differences in AA, levels of 5-HETE and 11-HETE in BAL were significantly 435 higher in Covid-19 than in non-Covid-19 patients, though other metabolites did not differ 436 between these groups (Figure 3C). When assessing leukocytes in BAL between the 437 patient groups, we found no differences in total or differential counts, with the exception 438 of lymphocyte numbers (Figure 3D, 3E). In contrast to eicosanoids, cytokine profiles in 439 Covid-19 and non-Covid-19 patients were similar (Figure 3F), suggesting that lipid 440 mediators contribute to the pathophysiological processes induced by SARS-CoV-2. 441 Interestingly, we observed a significant reduction in classical (Figure 3G) and 442 intermediate (Figure 3H) monocytes in BAL from Covid-19 patients. In parallel, CD14 443 and CD36 expression in monocyte was lower in BAL of Covid-19 than in that of non-444 Covid-19 patients (Figure 3I, 3J).

# 445 Acetylcholine, Cytokines and Eicosanoids are Higher in the Lung Micro446 Environment

We compared systemic and lung responses only in patients with severe/critical
Covid-19 and found significantly higher levels of cytokines in BAL than in blood (Figure
449 4A). When comparing lipid mediator levels in either compartment from the same Covid-

450 19 patients, we detected lower AA but higher levels of 5-HETE and 11-HETE in BAL 451 than in blood (Figure 4B, 4C, 4D). Previous results from our group<sup>3</sup> have shown that 452 eicosanoids contribute to ACh release. Therefore, we next measured ACh in patients with 453 Covid-19 and observed higher plasma levels of ACh in patients with Covid-19; in 454 addition, ACh was elevated in patients with severe/critical disease compared with those 455 with asymptomatic/moderate disease or healthy-participants (Figure 4E). Unexpectedly, 456 in patients with severe/critical Covid-19, ACh levels in BAL were 10-fold higher than 457 those in serum, and patients treated with glucocorticoids showed decreases in ACh in 458 both compartments (Figure 4F, 4G). Interesting, neutrophil counts were higher in BAL, 459 as these cells produce high levels of 5-HETE and IL-1 $\beta$ , both of which are mediators of ACh release<sup>30,31</sup> (Figure 4H). Correlation analysis was then performed to evaluate the 460 461 relationship between eicosanoids, cytokines, sCD14 and ACh in patients with Covid-19. 462 When comparing blood samples from all patients, we detected strong correlations 463 between ACh versus IL-1ß and moderate correlations between ACh versus AA. A 464 substantial number of interactions between AA and its metabolites and between cytokines 465 and eicosanoids were observed (Figure 4I; Figure S4A). Correlations among all 466 parameters were also observed in BAL (Figure 4J; Figure S4B). To evaluate the benefit 467 of glucocorticoid treatments and their relationship with eicosanoids, CD14 and ACh, we 468 analysed the intersections in a Venn diagram of blood and BAL from severe/critical 469 Covid-19. The results showed that treatment of Covid-19 with glucocorticoids did not 470 have a significant influence on eicosanoid or sCD14 release in patients with more severe 471 stages of disease; in critical patients, however, reductions of 44% and 65% in ACh levels 472 in blood and BAL, respectively, were observed (Figure 4K-4Q; Figure S5). These 473 findings suggest that the use of glucocorticoids has a positive effect on resolution of the

474 inflammatory process because they reduce ACh release, which directly or indirectly475 stimulates cell recruitment and proinflammatory mediator release.

# 476 Altered Expression of Acetylcholine and Arachidonic Acid Pathway Genes in Lung

477 Biopsies From Some Covid-19 Patients

478 In this study, we reanalysed the lung biopsy transcriptome from Covid-19 patients 479 to evaluate expression of ACh and AA pathway genes (Supplementary Appendix I). 480 These genes were coexpressed only in a single module (M1) that included genes related 481 to the ACh release cycle, AA metabolism, cholinergic and eicosanoid receptors, and 482 biomarkers of Covid-19 severity (Figure 5A; Table S4; Supplementary Appendix II). 483 Furthermore, expression of nearly all genes was upregulated in some deceased Covid-19 484 patients with long hospital stays and low viral loads (Figure 5B; Figure S6A; 485 Supplementary Appendix III). These differentially expressed genes populated the 486 biological network and are likely under the action of some hubs (Figure 5C; 487 Supplementary Appendix IV), such as oestrogen receptor II (ESR2) and albumin (ALB). 488 We identified a unique proinflammatory gene expression profile in lung biopsies related 489 to cholinergic and eicosanoid receptors (Figure 5H, 5I; Figure S6B, S6C). In combination 490 with the altered levels of ACh, AA, and AA metabolites found in patient from our cohort, 491 the transcriptome data reported herein strengthen the likelihood that these mediators 492 contribute to Covid-19 severity (Figure 5D-5G). Interestingly, lung samples from Covid-493 19 patients with short hospital stays and high viral loads did not present this unique expression profile of ACh or AA pathway genes (Figure 5H, 5I; Figure S6B, S6C). Some 494 495 Covid-19 patients treated versus not with glucocorticoid showed transcript expression of 496 monoglyceride lipase (MGLL) and N-acylethanolamine acid amidase (NAAA) and up-497 regulation of fatty acid amide hydrolase (FAAH), which are involved in the production 498 of AA from endocannabinoid (cases 3, 9, and 11; Figure 5B; Supplementary Appendix Page 21 of 84

III). Besides, we detected other DEGs in biopsy samples from Covid-19 patients
(glucocorticoid-treated versus non-treated) associated with AA, ACh, interferon
pathways, and Covid-19 biomarkers (Supplementary Appendix III).

# 502 Discussion

503 A consensus is building around the fatal effects of SARS-CoV-2 infection, which is 504 increasingly believed to cause death as a result of systemic hyperinflammation and multiorgan collapse<sup>32</sup>, secondary to systemic cytokine storms <sup>33–35</sup>. However, few studies have 505 compared pulmonary and systemic inflammation <sup>36</sup> or considered the contribution of 506 507 eicosanoids and neurotransmitters to these effects. In our study, we hypothesised that, in 508 Covid-19, pulmonary cells and leukocytes, in addition to cytokines, release eicosanoids 509 and ACh, mediating local and systemic manifestations. In patients with severe/critical 510 SARS-CoV-2 infection, we found that ACh, 5-HETE, 11-HETE, and cytokines were 511 more abundant in the lung than under systemic conditions. In contrast, only the levels of 512 AA were found to be higher in the circulation than in the BAL fluid. Interestingly, in 513 patients with severe/critical disease who were treated with corticosteroids, only ACh was 514 inhibited.

515 In our study, we compared the lung and systemic responses in association with the 516 lung transcriptome and demonstrated a robust correlation between lipid mediators, 517 neurotransmitters, and their receptors in SARS-CoV-2 infection. However, contrary to 518 what has been suggested by previous studies <sup>37,38</sup>, only small amounts of eicosanoids were 519 found in the plasma of patients with severe/critical disease, with significant differences 520 observed only in AA, 5-HETE, and 11-HETE. Interestingly, the levels of 5-HETE and 521 11-HETE were found to be remarkably higher in BAL, as well as AA in plasma, 522 suggesting that AA and its metabolites mediate responses to Covid-19. 5-HETE induces

neutrophil recruitment <sup>39</sup>, pulmonary oedema <sup>40</sup>, and ACh release <sup>30</sup>. It is released by 523 human neutrophils, and its esterified form promotes IL-8 secretion <sup>31</sup>. Unlike the 524 525 esterified form <sup>31</sup>, free-5-HETE did not inhibit NETs formation, a key event in Covid-19 <sup>41</sup>. Remarkably, 11-HETE originating from monocytes/macrophages <sup>42</sup>, endothelial cells 526 <sup>43</sup>, and platelets <sup>44</sup> is induced by hypoxia <sup>45</sup>, IL-1 $\beta$  <sup>46</sup>, contributes to ACh functions <sup>43</sup>, and 527 528 inhibits insulin release <sup>47</sup>. The involvement of AA was confirmed by bioinformatic 529 analyses that identified the expression or upregulation of genes related to AA metabolism 530 and eicosanoid receptors in some lung biopsies. These included the OXER1 gene, which 531 encodes a receptor for AA and **5-HETE** 48 which mediates neutrophil activation/recruitment 49,50. Our metabolomic analysis also showed an increase in the 532 533 plasma AA and linoleic acid levels, similar to a plasma lipidome performed by Schwarz 534 et al., suggesting a strong correlation between lipid mediators and Covid-19 severity <sup>51</sup>. 535 Accordingly, the ELOVL2 gene, which is involved in linoleic acid metabolism and AA synthesis <sup>52</sup>, was upregulated in lung biopsies. 536

537 The RNA expression of ALOX5, an enzyme that participates in lipid mediator production, is upregulated in some immune cell types from severe Covid-19 patients <sup>53</sup>, 538 539 and has been detected in the lung biopsies of deceased Covid-19 patients <sup>18</sup>. In contrast 540 to our lung transcriptome re-analysis findings, the expression of cytochrome p450 (CYP) 541 enzymes, which are also involved in lipid mediator generation, was not detected in the 542 peripheral blood mononuclear cells (PBMC) transcriptome re-analysis from severe 543 Covid-19 patients <sup>53</sup>. One possible explanation for this contradiction is that Covid-19 is a 544 heterogeneous illness composed of distinct tissue gene expression associated with Covid-545 19 severity and different immunopathological profiles in infected tissues <sup>18,54</sup>. This 546 immunological heterogeneity could be related to two types of evolution of severe Covid-547 19 patients, one associated with a high viral load and susceptibility to SARS-CoV-2

infection, a shorter hospitalisation time, and exudative diffuse alveolar damage, and 548 549 another associated with a low or undetectable viral load, a mixed lung histopathological 550 profile, and a longer hospitalisation time associated with non-homeostatic pulmonary inflammation <sup>18,54,55</sup>. In this context, we found that the expression levels of some lipid 551 552 mediators and ACh and AA pathway genes varied in the plasma and BAL samples of 553 severe/critical patients, which were found to be preferentially activated in the lungs of 554 deceased Covid-19 patients with low viral loads, long hospitalisation times, and 555 damaging lung inflammation.

556 Nevertheless, it remains unclear whether AA and linoleic acid contribute to host protection <sup>56</sup> and tissue damage, or whether they represent a viral escape mechanism. AA 557 558 is known to directly interact with the virus, reducing its viability and inducing membrane disturbances, disfavouring SARS-CoV-2 entry <sup>57–59</sup>. On the other hand, reduced plasma 559 560 AA levels may be associated with lung injury and poor outcomes in Covid-19 infection <sup>60</sup>. Within this context, Shen and et al. found lower concentrations of AA in survivors of 561 severe Covid-19 infection <sup>37</sup>. However, in the present study, the levels of AA were found 562 563 to be increased in the plasma of patients who died from severe Covid-19, suggesting that 564 the potential benefits of AA are overcome by a higher production of its proinflammatory 565 metabolites, 5-HETE and 11-HETE. Interestingly, in our cohort, AA, 5-HETE, and 11-566 HETE were not altered in the plasma or BAL fluid of patients with severe/critical Covid-567 19 infection who had received glucocorticoid treatment. This may be explained by the fact that AA, in addition to calcium-activated-PLA<sub>2</sub><sup>61</sup> also originates from 568 glucocorticoid-insensitive phospholipase <sup>62</sup>, adipocyte destruction <sup>63</sup>, linoleic acid <sup>64</sup>, or 569 the degradation of endocannabinoids by FAAH<sup>65</sup>, a macrophage enzyme detected in 570 571 SARS-CoV-2-infected patients <sup>66</sup>. Notably, some CVL Covid-19 patients, regardless of 572 whether they were treated or not with glucocorticoids, showed transcript expression of

573 MGLL and NAAA, as well as an up-regulation of FAAH and all of the enzymes involved in the production of AA from endocannabinoid <sup>67</sup>. In addition, we detected other DEGs 574 575 in biopsy samples (glucocorticoid-treated versus non-treated) associated with AA, ACh, 576 interferon pathways, and Covid-19 biomarkers. Glucocorticoids have been used widely 577 to reduce the morbidity and mortality rates of Covid-19 patients, but have not been effective for all patients <sup>68</sup>. The mortality rate for glucocorticoid-treated hospitalised 578 579 Covid-19 patients from our cohort was higher than that reported in the RECOVERY trial 580 and similar to that described in the CoDEX trial conducted in Brazil<sup>69</sup>. High mortality 581 rates could be associated with several factors, including a low mean PaO<sub>2</sub>:FiO<sub>2</sub> ratio and overloaded public health systems in countries with limited resources, such as Brazil 69 582 and as well as glucocorticoid dose, initiation, and duration of therapy <sup>70,71</sup>. In addition, 583 584 the precise threshold at which a patient should be treated with glucocorticoids, that is to 585 avoid the manifestation of adverse effects associated with comorbidities and inefficient clearance of SARS-CoV-2, remains unclear <sup>72</sup>. However, a delayed start of glucocorticoid 586 587 therapy could result in a lack of response due to patients reaching a point of no return, as 588 suggested previously by our research group with regards to scorpion poisoning, which triggers a sterile inflammatory process<sup>3</sup>. On the other hand, considering that Covid-19 is 589 590 a non-sterile hyperinflammatory disease, the administration of glucocorticoids is more 591 effective after the initial phase in which hospitalised patients have low or undetectable 592 viral loads <sup>18,68</sup>. Our data suggest that SARS-CoV-2 infection activates the glucocorticoid-593 insensitive release of AA metabolites associated with Covid-19 severity. Hence, lipid 594 mediator production pathways could be important molecular targets for Covid-19 treatment, as suggested by other researchers <sup>53</sup>. Accordingly, we suggested that, in order 595 596 to improve the benefits of glucocorticoid therapy in hospitalized patients, who show

lower or undetectable viral loads, patients should be treated as soon as possible incombination with AA metabolism inhibitors.

CD36 is expressed in several cells <sup>73,74</sup>, where it induces Ca<sup>++</sup> mobilisation, cell 599 signalling, LTB<sub>4</sub> production, and cellular fatty acid uptake  $^{75-78}$ . The maintenance of high 600 601 free-AA levels in patients with severe/critical glucocorticoid-treated disease may result 602 from the reduction of CD36 on macrophage membranes. Intriguingly, CD36 is a gustatory lipid sensor <sup>79</sup>, whose deficit in cell membranes may account for the symptoms of ageusia, 603 604 anosmia, diarrhoea, hyperglycaemia, platelet aggregation, and cardiovascular disturbances experienced by Covid-19 patients 75-77. CD36 is a substrate of matrix 605 606 metalloproteinase-9 (MMP-9) and disintegrin metalloproteinase domain-containing protein 17 (ADAM17)<sup>80,81</sup>. Decreased CD36 expression in Covid-19 patients most likely 607 608 results from the action of these enzymes. MMP-9 is produced by neutrophils <sup>82</sup>, induced 609 by TNF- $\alpha^{83}$ , unaffected by glucocorticoids, and associated with respiratory syndrome in Covid-19<sup>84</sup>. ADAM17 has been described as a target for Covid-19 treatment<sup>85</sup>. 610

611 In agreement with previous reports <sup>1,34,86,87</sup>, in the present study, high 612 concentrations of IL-6, IL-8, and IL-10 were detected, along with insignificant levels of 613 IL-1 $\beta$  in plasma. In contrast, the inflammatory cytokine TNF- $\alpha$  was found at the lowest 614 concentration in BAL fluid, and insignificant levels were detected in the blood. The low 615 levels of TNF-a production are correlated with the decreased counts of intermediate 616 monocytes in the blood and BAL, which are major sources of this cytokine <sup>88</sup>. As 617 expected, in the BAL from patients with severe/critical Covid-19, the levels of IL-8, IL-618 6, IL-1 $\beta$ , TNF- $\alpha$ , and IL-10 were significantly higher compared with the plasma of all 619 participants, or when paired with patients' own plasma. Notably, in BAL, the most abundant cytokine was IL-8, which is produced by neutrophils<sup>89</sup>, lung macrophages<sup>90</sup>, 620 and bronchial epithelial cells <sup>10</sup>, and is induced by 5-HETE <sup>31</sup> and ACh <sup>10</sup>. Interestingly, 621

622 BAL fluid from non-Covid-19 patients also presented a high concentration of cytokines 623 that did not differ from that of patients with Covid-19. This suggests that cytokine storms 624 are not a key differential factor in this disease. Contrary to our expectations, 625 glucocorticoids did not alter cytokine production (Table S7). As a result, we suggest that, 626 regardless of whether Covid-19 is treated with glucocorticoids, cross-talk occurs between cvtokines, lipid mediators, and ACh, as previously reported  $^{2,3,91}$ . IL-1 $\beta$  induces 11-HETE 627 <sup>46</sup>; arterial relaxation induced by ACh is mediated by 11-HETE and is inhibited by 628 indomethacin<sup>43</sup>. In our studies on scorpion envenomation, ACh release was found to be 629 630 mediated by PGE<sub>2</sub>-induced by IL-1 $\beta$  and inhibited by indomethacin <sup>3</sup>. In the present study, comparing AA, 5-HETE, 11-HETE, cytokine, and receptor expression 631 632 demonstrated the absence of glucocorticoid effects. These results, in addition to the results of other studies from our laboratory<sup>3</sup>, suggest that glucocorticoids did not have an 633 634 effect in our cohort. This was most likely due to the fact that treatment was started late, 635 namely after inflammation has been triggered by infection. In this context, Covid-19 636 patients could had already reached the point of no return, similar to what has been 637 previously described in scorpion envenomation  $^{3}$ .

As predicted by Virgilis and Giovani<sup>92</sup>, neurotransmitters are produced in Covid-638 639 19. ACh induces mucus secretion, bronchoconstriction, lung inflammation and remodelling <sup>9</sup>, cardiac dysfunction in scorpionism <sup>3</sup>, NETs formation <sup>93</sup>, IL-8 release <sup>10</sup>, 640 thrombosis <sup>94</sup>, and obesity-related severity <sup>95</sup>. In addition to the nervous system <sup>4</sup>, ACh is 641 also produced by pulmonary vessels <sup>96</sup>, airway epithelial cells <sup>6</sup>, and immune cells <sup>5</sup>. When 642 binding to anti-inflammatory neural nicotinic receptors induces AA release <sup>97</sup>, it inhibits 643 nicotine receptors <sup>97</sup>, which are highly expressed in lungs <sup>98</sup>. In our cohort, a correlation 644 645 between the AA and ACh levels and the severity of Covid-19 infection was observed, 646 which was reinforced by the results of our bioinformatics study. Our lung transcriptome

647 re-analyses showed that ACh release cycle genes were activated, including acetylcholine-648 synaptic release (synaptotagmin 1) and neuronal choline transporter (Solute Carrier 649 Family 5 Member 7, SLC5A7). Accordingly, SLC5A7 gene expression was higher in the lung of patients who died from Covid-19 infection than patients who survived <sup>99</sup>. Because 650 this gene mediates the translocation of choline into lung epithelial cells <sup>100</sup> and 651 652 macrophages <sup>101</sup>, the production of ACh in BAL may also depend on non-neuronal cells. 653 Indeed, the ACh repressor gene in non-neural cells (RE1 Silencing Transcription Factor) 654 is reduced in the lungs of patients who died of Covid-19<sup>99</sup>. The activation of Tlymphocyte EP4 induces the release of ACh <sup>102</sup>, suggesting that AA metabolites 655 656 contribute to the release of ACh from lung and immune cells. As expected, ACh 657 production in patients with severe/critical disease was found to be inhibited by glucocorticoids, since this drug blocks ACh production by lung epithelial cells <sup>103–105</sup>. 658 659 Patients with Covid-19 (mostly methylprednisolone-treated patients) showed lower plasma levels of choline and higher plasma levels of phosphocholine <sup>37</sup>. In addition, a 660 661 distinct pattern of ACh receptor mRNA expression was found in patients who died of 662 Covid-19 (mainly in the CVL-lengthy hospital stay group). This profile is characterised 663 by low levels of expression of the nicotinic receptor encoded by cholinergic receptor 664 nicotinic alpha 7 subunit gene (CHRNA7) and increased levels of expression of two 665 nicotinic and one muscarinic receptor in deceased-CVL compared to deceased non-666 Covid-19 patients. These proteins are encoded by the cholinergic nicotinic alpha 3 subunit 667 gene (CHRNA3), the cholinergic nicotinic receptor 5 subunit gene (CHRNA5), and the 668 muscarinic cholinergic receptor 3 gene (CHRM3), respectively. These three upregulated 669 genes were also co-expressed and associated with pulmonary inflammatory disorders  $^{9,106-110}$ . Notably, SARS-CoV-2 spike glycoprotein interacts with the  $\alpha$ 7 nicotinic 670

acetylcholine receptor, which may compromise the cholinergic anti-inflammatory
 pathway<sup>111</sup>.

673 The ACh-nicotinic receptor, encoded by CHRNA7, is expressed in various lung cells and macrophages <sup>112</sup>. It displays extensive anti-inflammatory activities, including 674 675 the inhibition of pro-inflammatory cytokine production <sup>113</sup>, the recruitment of neutrophils <sup>114</sup>, and the reduction of CD14 expression in human monocytes <sup>115</sup>. The increased degrees 676 of inflammation in the BAL fluid of patients with severe/critical Covid-19 may be 677 678 associated with the lower levels of anti-inflammatory CHRNA7 expression. However, a reduction in monocyte CD14 may result from high levels of IL-6 production <sup>116</sup>, since the 679 680 levels of CHRNA7 expression were very low. Interestingly, the ACh-M3 receptor in 681 immune cells has been found to be up-regulated by ACh, which mediates its proinflammatory actions, including the production of IL-8 and the recruitment of neutrophils 682 683 <sup>117</sup>. Furthermore, the interaction between ACh and its receptor triggers the AA-derived release of eicosanoids, including 5-HETE <sup>97,118,119</sup>. Remarkably, vitamin D modulates the 684 685 ACh-M3 receptor <sup>120</sup>, which may explain its beneficial effects in the prevention of Covid-686 19<sup>121</sup>. Based on the anti-inflammatory effects of nicotinic receptors and the 687 downregulation of the SARS-CoV-2 receptor ACE2 promoted by nicotine, therapies involving nicotinic receptors have been proposed to treat Covid-19 infection <sup>122,123</sup>. In 688 fact, based on these findings, an acetylcholinesterase inhibitor <sup>124,125</sup> and a nicotinic 689 receptor agonist have been tested <sup>126,127</sup>. However, recent studies have demonstrated that 690 nicotine and smoking increase ACE2 receptor density <sup>128,129</sup>, and that the potential 691 beneficial effects of nicotine were restricted to a small group of individuals <sup>130</sup>. Our 692 693 findings provide a warning that precautions should be taken when considering the 694 therapeutic use of nicotinic agonists, since patients with severe/critical Covid-19 were 695 found to release high amounts of ACh, in addition to showing increased levels of M3-

receptor expression. Due to the antiviral and anti-inflammatory effects of AA, it has been
proposed to treat Covid-19 patients <sup>60</sup>. Nevertheless, AA may be not be an adequate
therapeutic target, based on both our findings and previous studies <sup>131</sup>, which have shown
that AA can favour hyperinflammation and lethality in Covid-19 infection. In conclusion,
ACh, AA, 5-HETE, and 11-HETE mediate the innate immune response to SARS-CoV-2
and may define the outcome of infection.

702 Covid-19 severity can be associated with disruption of homeostatic lipidome and 703 metabolic alterations and this phenomenon may be influenced by comorbidities/risk 704 factors related to the infection. Our findings demonstrated that (i) high plasma levels of 705 ACh and lipid mediators positively correlated with Covid-19 severity; and (ii) only 706 hypertension and/or age were confounding variables for analyzing the association of high 707 plasma levels of AA, 5-HETE, and ACh with disease severity (Table S7). Similarly, the 708 correlation between altered plasma profile of lipid mediators and Covid-19 severity is 709 associated with selective comorbidities - mainly high body mass index (BMI) - but 710 poorly associated with gender, advanced age, and diabetes. However, the correlation 711 between altered AA and/or 5-HETE levels and disease severity is associated with male 712 gender, hypertension, and heart disease, but not BMI<sup>53</sup>.

713 We also examined whether glucocorticoid-therapy interfered with the potential 714 effect of some confounding variables on the correlation between high ACh levels and 715 Covid-19 severity in severe/critical patients. Despite the relatively underrepresented 716 samples from non-glucocorticoid treated patients, no confounding variable significantly 717 affected the correlation between plasma and BAL ACh levels and Covid-19 severity in 718 severe/critical patients treated or not with glucocorticoids (Table S8). The altered plasma 719 and BAL levels of the lipid mediators AA, 5-HETE, and 11-HETE in severe/critical 720 patients were associated with the disease severity but not with the confounding variables

tested (Table S9). Altogether, the findings here reported suggest that age and/or hypertension are significant confounding variables for analyzing the association between increased levels of cholinergic and lipid mediators and Covid-19 severity. Also, the confounding variables tested probably did not modify the inhibitory action of glucocorticoids on plasma and BAL ACh levels in severe/critical patients.

726 To the best of our knowledge, this study is the first to demonstrate that the lung 727 inflammatory process and poor outcomes of patients with Covid-19 infection are 728 associated with high levels of lipid mediators and ACh, produced via a partially 729 glucocorticoid-insensitive pathway. Glucocorticoid therapy was found to lower only the 730 levels of ACh. Thus, to improve the benefits of glucocorticoid therapy, we suggest that 731 treatment in hospitalised patients be started early and be preferentially administered to 732 patients with low or undetectable viral loads and harmful lung inflammation in 733 combination with AA metabolism inhibitors.

## 734 Conclusions

We demonstrate for the first time that the lung inflammatory process and worse outcomes in Covid-19 are associated with lipid mediators and ACh, which are produced through a partially glucocorticoid-insensitive pathway. To improve the benefits of glucocorticoid therapy, we suggest that it should be started early in severe/critical hospitalized patients and in combination with AA metabolism inhibitors.

740

741

742

# 743 **References**

744	1.	Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019
745		novel coronavirus in Wuhan, China. Lancet 2020;395(10223):497–506.
746	2.	Esser-von Bieren J. Immune-regulation and -functions of eicosanoid lipid
747		mediators. Biol. Chem. 2017;
748	3.	Reis M, Rodrigues F, Lautherbach N, et al. Interleukin-1 receptor-induced PGE2
749		production controls acetylcholine-mediated cardiac dysfunction and mortality
750		during scorpion envenomation. Nat Commun 2020;11(1).
751	4.	McGovern AE, Mazzone SB. Neural regulation of inflammation in the airways
752		and lungs. Auton Neurosci Basic Clin 2014;
753	5.	Wessler I, Kirkpatrick CJ. Cholinergic signaling controls immune functions and
754		promotes homeostasis. Int. Immunopharmacol. 2020;
755	6.	Proskocil BJ, Sekhon HS, Jia Y, et al. Acetylcholine is an autocrine or paracrine
756		hormone synthesized and secreted by airway bronchial epithelial cells.
757		Endocrinology 2004;
758	7.	Chang EH, Chavan SS, Pavlov VA. Cholinergic control of inflammation,
759		metabolic dysfunction, and cognitive impairment in obesity-associated disorders:
760		Mechanisms and novel therapeutic opportunities. Front. Neurosci. 2019;
761	8.	Roy A, Guatimosim S, Prado VF, Gros R, Prado MAM. Cholinergic activity as a
762		new target in diseases of the heart. Mol Med 2014;
763	9.	Kistemaker LEM, Gosens R. Acetylcholine beyond bronchoconstriction: roles in
764		inflammation and remodeling. Trends Pharmacol Sci 2015;36(3):164-71.
765	10.	Profita M, Bonanno A, Siena L, et al. Acetylcholine mediates the release of IL-8
766		in human bronchial epithelial cells by a NFkB/ERK-dependent mechanism. Eur J
767		Pharmacol 2008;

768	11.	Shields MD, Riedler J. Bronchoalveolar lavage and tracheal aspirate for
769		assessing airway inflammation in children. Am J Respir Crit Care Med
770		2000;162(2 II).
771	12.	Schindelin J, Rueden CT, Hiner MC, Eliceiri KW. The ImageJ ecosystem: An
772		open platform for biomedical image analysis. Mol Reprod Dev 2015;82(7-
773		8):518–29.
774	13.	Sorgi CA, Peti APF, Petta T, et al. Data descriptor: Comprehensive high-
775		resolution multiple-reaction monitoring mass spectrometry for targeted
776		eicosanoid assays. Sci Data 2018;
777	14.	Chambers MC, MacLean B, Burke R, et al. A cross-platform toolkit for mass
778		spectrometry and proteomics. Nat. Biotechnol. 2012;
779	15.	Yu T, Park Y, Johnson JM, Jones DP. apLCMS-adaptive processing of high-
780		resolution LC/MS data. Bioinformatics 2009;
781	16.	Li S, Park Y, Duraisingham S, et al. Predicting Network Activity from High
782		Throughput Metabolomics. PLoS Comput Biol 2013;
783	17.	Kuri-Cervantes L, Pampena MB, Meng W, et al. Comprehensive mapping of
784		immune perturbations associated with severe COVID-19. Sci Immunol 2020;
785	18.	Desai N, Neyaz A, Szabolcs A, et al. Temporal and spatial heterogeneity of host
786		response to SARS-CoV-2 pulmonary infection. Nat Commun [Internet]
787		2020;11(1):6319. Available from: http://www.nature.com/articles/s41467-020-
788		20139-7
789	19.	Edgar R, Domrachev M, Lash AE. Gene Expression Omnibus: NCBI gene
790		expression and hybridization array data repository. Nucleic Acids Res 2002;
791	20.	Russo PST, Ferreira GR, Cardozo LE, et al. CEMiTool: A Bioconductor package
792		for performing comprehensive modular co-expression analyses. BMC

793		Bioinformatics 2018;
794	21.	Jassal B, Matthews L, Viteri G, et al. The reactome pathway knowledgebase.
795		Nucleic Acids Res 2020;
796	22.	Love MI, Huber W, Anders S. Moderated estimation of fold change and
797		dispersion for RNA-seq data with DESeq2. Genome Biol 2014;
798	23.	Benjamini Y, Hochberg Y. Controlling the False Discovery Rate: A Practical and
799		Powerful Approach to Multiple Testing. J R Stat Soc Ser B 1995;
800	24.	Stark C, Breitkreutz BJ, Reguly T, Boucher L, Breitkreutz A, Tyers M.
801		BioGRID: a general repository for interaction datasets. Nucleic Acids Res 2006;
802	25.	Csardi G, Nepusz T. The igraph software package for complex network research.
803		InterJournal Complex Syst 2006;
804	26.	Maintainer MB, Bojanowski M. Package "intergraph" Type Package Title
805		Coercion Routines for Network Data Objects. 2016;
806	27.	Tyner S, Briatte F, Hofmann H. Network visualization with ggplot2. R J
807		2017;9(1):27–59.
808	28.	Taylor R. Interpretation of the Correlation Coefficient: A Basic Review. J
809		Diagnostic Med Sonogr 1990;
810	29.	Abreu-Filho PG, Tarragô AM, Costa AG, et al. Plasma Eicosanoid Profile in
811		Plasmodium vivax Malaria: Clinical Analysis and Impacts of Self-Medication.
812		Front Immunol 2019;
813	30.	Fukunaga Y, Mine Y, Yoshikawa S, Takeuchi T, Hata F, Yagasaki O. Role of
814		prostacyclin in acetylcholine release from myenteric plexus of guinea-pig ileum.
815		Eur J Pharmacol 1993;233(2–3):237–42.
816	31.	Clark SR, Guy CJ, Scurr MJ, et al. Esterified eicosanoids are acutely generated
817		by 5-lipoxygenase in primary human neutrophils and in human and murine

818		infection. Blood 2011;
819	32.	Chen G, Wu D, Guo W, et al. Clinical and immunological features of severe and
820		moderate coronavirus disease 2019. J Clin Invest 2020;130(5):2620-9.
821	33.	Knight DS, Kotecha T, Razvi Y, et al. COVID-19: Myocardial injury in
822		survivors. Circulation. 2020;
823	34.	Del Valle DM, Kim-Schulze S, Huang HH, et al. An inflammatory cytokine
824		signature predicts COVID-19 severity and survival. Nat Med 2020;
825	35.	Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ. COVID-
826		19: consider cytokine storm syndromes and immunosuppression. Lancet. 2020;
827	36.	Polidoro RB, Hagan RS, de Santis Santiago R, Schmidt NW. Overview:
828		Systemic Inflammatory Response Derived From Lung Injury Caused by SARS-
829		CoV-2 Infection Explains Severe Outcomes in COVID-19. Front. Immunol.
830		2020;
831	37.	Shen B, Yi X, Sun Y, et al. Proteomic and Metabolomic Characterization of
832		COVID-19 Patient Sera. Cell 2020;
833	38.	Delafiori J, Claudio Navarro L, Focaccia Siciliano R, et al. Covid-19 automated
834		diagnosis and risk assessment through Metabolomics and Machine-Learning.
835		2020.
836	39.	Bittleman DB, Casale TB. 5-Hydroxyeicosatetraenoic acid (HETE)-induced
837		neutrophil transcellular migration is dependent upon enantiomeric structure. Am
838		J Respir Cell Mol Biol 1995;12(3):260–7.
839	40.	Harder DR. Pressure-induced myogenic activation of cat cerebral arteries is
840		dependent on intact endothelium. Circ Res 1987;
841	41.	Barnes BJ, Adrover JM, Baxter-Stoltzfus A, et al. Targeting potential drivers of
842		COVID-19: Neutrophil extracellular traps. J. Exp. Med. 2020;

843	42.	Kita Y, Takahashi T, Uozumi N, Nallan L, Gelb MH, Shimizu T. Pathway-
844		oriented profiling of lipid mediators in macrophages. Biochem Biophys Res
845		Commun 2005;
846	43.	Gauthier KM, Goldman DH, Aggarwal NT, Chawengsub Y, Falck JR, Campbell
847		WB. Role of arachidonic acid lipoxygenase metabolites in acetylcholine-induced
848		relaxations of mouse arteries. Am J Physiol - Hear Circ Physiol 2011;
849	44.	Rauzi F, Kirkby NS, Edin ML, et al. Aspirin inhibits the production of
850		proangiogenic 15(S)-HETE by platelet cyclooxygenase-1. FASEB J 2016;
851	45.	Berna N, Arnould T, Remacle J, Michiels C. Hypoxia-induced increase in
852		intracellular calcium concentration in endothelial cells: Role of the Na+-glucose
853		cotransporter. J Cell Biochem 2002;
854	46.	López S, Vila L, Breviario F, de Castellarnau C. Interleukin-1 increases 15-
855		hydroxyeicosatetraenoic acid formation in cultured human endothelial cells.
856		Biochim Biophys Acta (BBA)/Lipids Lipid Metab 1993;
857	47.	Metz SA, Murphy RC, Fujimoto W, . Effects on glucose-induced insulin
858		secretion of lipoxygenase-derived metabolites of arachidonic acid. Diabetes
859		1984;33(2):119–24.
860	48.	Hosoi T, Koguchi Y, Sugikawa E, et al. Identification of a novel human
861		eicosanoid receptor coupled to Gi/o. J Biol Chem 2002;
862	49.	Powell WS, Rokach J, ., . The eosinophil chemoattractant 5-oxo-ETE and the
863		OXE receptor. Prog. Lipid Res. 2013;
864	50.	Powell WS, Rokach J. Targeting the OXE receptor as a potential novel therapy
865		for asthma. Biochem Pharmacol 2020;179:113930.
866	51.	Schwarz B, Sharma L, Roberts L, et al. Cutting Edge: Severe SARS-CoV-2
867		Infection in Humans Is Defined by a Shift in the Serum Lipidome, Resulting in
D $D$ $D$ $D$ $D$ $D$ $D$ $D$ $D$ $D$		
---------------------------------------		
---------------------------------------		

- 869 2020;ji2001025. Available from:
- 870 http://www.jimmunol.org/content/early/2020/12/04/jimmunol.2001025.abstract
- 871 52. Hanna VS, Hafez EAA. Synopsis of arachidonic acid metabolism: A review. J.
- 872 Adv. Res. 2018;
- 53. Schwarz B, Sharma L, Roberts L, et al. Severe SARS-CoV-2 infection in humans
- is defined by a shift in the serum lipidome resulting in dysregulation of
- eicosanoid immune mediators. Res Sq 2020;
- 876 54. Nienhold R, Ciani Y, Koelzer VH, et al. Two distinct immunopathological
- 877 profiles in autopsy lungs of COVID-19. Nat Commun [Internet]
- 878 2020;11(1):5086. Available from: https://doi.org/10.1038/s41467-020-18854-2
- 879 55. Pairo-Castineira E, Clohisey S, Klaric L, et al. Genetic mechanisms of critical

880 illness in Covid-19. Nature [Internet] 2020; Available from:

- 881 https://doi.org/10.1038/s41586-020-03065-y
- 56. Taha AY. Linoleic acid–good or bad for the brain? npj Sci. Food. 2020;
- 883 57. Kohn A, Gitelman J, Inbar M. Unsaturated free fatty acids inactivate animal
- enveloped viruses. Arch Virol 1980;
- 58. Das UN. Arachidonic acid and other unsaturated fatty acids and some of their
  metabolites function as endogenous antimicrobial molecules: A review. J. Adv.
  Res. 2018;
- 888 59. Chandrasekharan JA, Sharma-Walia N. Arachidonic acid derived lipid mediators
- 889 influence Kaposi's sarcoma-associated herpesvirus infection and pathogenesis.
- 890 Front. Microbiol. 2019;
- 891 60. Das UN. Bioactive Lipids in COVID-19-Further Evidence. Arch Med Res 2020;
- 892 61. Nakano T, Ohara O, Teraoka H, Arita H. Glucocorticoids suppress group II

893		phospholipase A2 production by blocking mRNA synthesis and post-
894		transcriptional expression. J Biol Chem 1990;
895	62.	Kobza Black A, Greaves M, Hensby C. The effect of systemic prednisolone on
896		arachidonic acid, and prostaglandin E2 and F2 alpha levels in human cutaneous
897		inflammation. Br J Clin Pharmacol 1982;
898	63.	Hu X, Cifarelli V, Sun S, Kuda O, Abumrad NA, Su X. Major role of adipocyte
899		prostaglandin E2 in lipolysis-induced macrophage recruitment. J Lipid Res 2016;
900	64.	Alzoghaibi MA, Walsh SW, Willey A, Yager DR, Fowler AA, Graham MF.
901		Linoleic acid induces interleukin-8 production by Crohn's human intestinal
902		smooth muscle cells via arachidonic acid metabolites. Am J Physiol -
903		Gastrointest Liver Physiol 2004;
904	65.	Ahn K, McKinney MK, Cravatt BF. Enzymatic pathways that regulate
905		endocannabinoid signaling in the nervous system. Chem Rev 2008;108(5):1687-
906		707.
907	66.	Grant RA, Morales-Nebreda L, Markov NS, et al. Alveolitis in severe SARS-
908		CoV-2 pneumonia is driven by self-sustaining circuits between infected alveolar
909		macrophages and T cells. bioRxiv 2020;
910	67.	Malcher-Lopes R, Franco A, Tasker JG. Glucocorticoids shift arachidonic acid
911		metabolism toward endocannabinoid synthesis: A non-genomic anti-
912		inflammatory switch. Eur. J. Pharmacol. 2008;
913	68.	The RECOVERY Collaborative G. Dexamethasone in Hospitalized Patients with
914		Covid-19 — Preliminary Report. N Engl J Med 2020;
915	69.	Tomazini BM, Maia IS, Cavalcanti AB, et al. Effect of Dexamethasone on Days
916		Alive and Ventilator-Free in Patients with Moderate or Severe Acute Respiratory
917		Distress Syndrome and COVID-19: The CoDEX Randomized Clinical Trial.

918		JAMA - J Am Med Assoc 2020;
919	70.	Tang Y, Liu J, Zhang D, Xu Z, Ji J, Wen C. Cytokine Storm in COVID-19: The
920		Current Evidence and Treatment Strategies. Front. Immunol. 2020;
921	71.	Ye Q, Wang B, Mao J, . The pathogenesis and treatment of the 'Cytokine
922		Storm'' in COVID-19.' J. Infect. 2020;
923	72.	Prescott HC, Rice TW. Corticosteroids in COVID-19 ARDS: Evidence and Hope
924		during the Pandemic. JAMA - J. Am. Med. Assoc. 2020;
925	73.	Noushmehr H, D'Amico E, Farilla L, et al. Fatty acid translocase (FAT/CD36) is
926		localized on insulin-containing granules in human pancreatic $\beta$ -cells and
927		mediates fatty acid effects on insulin secretion. Diabetes 2005;
928	74.	Glatz JFC, Luiken J. From fat to FAT (CD36/SR-B2): Understanding the
929		regulation of cellular fatty acid uptake. Biochimie. 2017;
930	75.	Febbraio M, Hajjar DP, Silverstein RL. CD36: A class B scavenger receptor
931		involved in angiogenesis, atherosclerosis, inflammation, and lipid metabolism. J.
932		Clin. Invest. 2001;
933	76.	Glatz JFC, Luiken JJFP, Bonen A. Membrane fatty acid transporters as regulators
934		of lipid metabolism: Implications for metabolic disease. Physiol. Rev. 2010;
935	77.	Pepino MY, Kuda O, Samovski D, Abumrad NA. Structure-function of CD36
936		and importance of fatty acid signal transduction in fat metabolism. Annu. Rev.
937		Nutr. 2014;
938	78.	Zoccal KF, Gardinassi LG, Sorgi CA, et al. CD36 shunts eicosanoid metabolism
939		to repress CD14 Licensed interleukin-1 $\beta$ release and inflammation. Front
940		Immunol 2018;
941	79.	Khan NA, Besnard P. Oro-sensory perception of dietary lipids: New insights into
942		the fat taste transduction. Biochim. Biophys. Acta - Mol. Cell Biol. Lipids. 2009;

- 943 80. Deleon-Pennell KY, Tian Y, Zhang B, et al. CD36 Is a Matrix Metalloproteinase-
- 944 9 Substrate That Stimulates Neutrophil Apoptosis and Removal during Cardiac
- 945 Remodeling. Circ Cardiovasc Genet 2016;
- 946 81. Novak ML, Thorp EB. Shedding light on impaired efferocytosis and
- 947 nonresolving inflammation. Circ. Res. 2013;
- 948 82. Cundall M, Sun Y, Miranda C, Trudeau JB, Barnes S, Wenzel SE. Neutrophil-
- 949 derived matrix metalloproteinase-9 is increased in severe asthma and poorly
- 950 inhibited by glucocorticoids. J Allergy Clin Immunol 2003;
- 951 83. Hozumi A, Nishimura Y, Nishiuma T, Kotani Y, Yokoyama M. Induction of
- 952 MMP-9 in normal human bronchial epithelial cells by TNF- $\alpha$  via NF- $\kappa$ B-
- 953 mediated pathway. Am J Physiol Lung Cell Mol Physiol 2001;
- 954 84. Ueland T, Holter JC, Holten AR, et al. Distinct and early increase in circulating
- 955 MMP-9 in COVID-19 patients with respiratory failure: MMP-9 and respiratory
- 956 failure in COVID-19. J. Infect. 2020;
- 957 85. Palau V, Riera M, Soler MJ. ADAM17 inhibition may exert a protective effect
  958 on COVID-19. Nephrol Dial Transplant 2020;
- 86. Laing AG, Lorenc A, del Molino del Barrio I, et al. A dynamic COVID-19
- 960 immune signature includes associations with poor prognosis. Nat Med 2020;
- 961 87. Zhao Y, Qin L, Zhang P, et al. Longitudinal COVID-19 profiling associates IL-
- 962 1RA and IL-10 with disease severity and RANTES with mild disease. JCI Insight
  963 2020;
- 88. Belge K-U, Dayyani F, Horelt A, et al. The Proinflammatory CD14 + CD16 +
- 965 DR ++ Monocytes Are a Major Source of TNF . J Immunol 2002;
- 966 89. Kunkel SL, Standiford T, Kasahara K, Strieter RM. Interleukin-8 (IL-8): The
- 967 major neutrophil chemotactic factor in the lung. Exp Lung Res 1991;

968	90.	Kunkel TA, Bebenek K, McClary J. Efficient site-directed mutagenesis using
969		uracil-containing DNA. Methods Enzymol 1991;
970	91.	Zoccal KF, Sorgi CA, Hori JI, et al. Opposing roles of LTB4 and PGE2 in
971		regulating the inflammasome-dependent scorpion venom-induced mortality. Nat
972		Commun 2016;
973	92.	De Virgiliis F, Di Giovanni S. Lung innervation in the eye of a cytokine storm:
974		neuroimmune interactions and COVID-19. Nat Rev Neurol 2020;
975	93.	Carmona-Rivera C, Purmalek MM, Moore E, et al. A role for muscarinic
976		receptors in neutrophil extracellular trap formation and levamisole-induced
977		autoimmunity. JCI Insight 2017;
978	94.	do Espírito Santo DA, Lemos ACB, Miranda CH, . In vivo demonstration of
979		microvascular thrombosis in severe COVID-19. J Thromb Thrombolysis 2020;
980	95.	Supuran CT, Di Fiore A, De Simone G. Carbonic anhydrase inhibitors as
981		emerging drugs for the treatment of obesity. Expert Opin. Emerg. Drugs. 2008;
982	96.	Cavallotti C, Bruzzone P, Mancone M, Leali FMT. Distribution of
983		acetylcholinesterase and cholineacetyl-transferase activities in coronary vessels
984		of younger and older adults. Geriatr Gerontol Int 2004;
985	97.	Vijayaraghavan S, Huang B, Blumenthal EM, Berg DK. Arachidonic acid as a
986		possible negative feedback inhibitor of nicotinic acetylcholine receptors on
987		neurons. J Neurosci 1995;
988	98.	Mabley J, Gordon S, Pacher P. Nicotine exerts an anti-inflammatory effect in a
989		murine model of acute lung injury. Inflammation 2011;
990	99.	Blanco-Melo D, Nilsson-Payant BE, Liu WC, et al. Imbalanced Host Response to
991		SARS-CoV-2 Drives Development of COVID-19. Cell 2020;
992	100.	Horiguchi K, Horiguchi S, Yamashita N, et al. Expression of SLURP-1, an

- 993 endogenous α7 nicotinic acetylcholine receptor allosteric ligand, in murine
- bronchial epithelial cells. J Neurosci Res 2009;
- 995 101. Schirmer SU, Eckhardt I, Lau H, et al. The cholinergic system in rat testis is of
  996 non-neuronal origin. Reproduction 2011;
- 997 102. Suenaga A, Fujii T, Ogawa H, et al. Up-regulation of lymphocytic cholinergic
- 998 activity by ONO-4819, a selective prostaglandin EP4 receptor agonist, in MOLT-

999 3 human leukemic T cells. Vascul Pharmacol 2004;

- 1000 103. Reinheimer T, Münch M, Bittinger F, Racké K, Kirkpatrick CJ, Wessler I.
- 1001 Glucocorticoids mediate reduction of epithelial acetylcholine content in the

airways of rats and humans. Eur J Pharmacol 1998;

- 1003 104. Gross I, Ballard PL, Ballard RA, Jones CT, Wilson CM. Corticosteroid
- stimulation of phosphatidylcholine synthesis in cultured fetal rabbit lung:
- 1005 Evidence for de novo protein synthesis mediated by glucocorticoid receptors.

1006 Endocrinology 1983;

1007 105. Nakamura T, Fujiwara R, Ishiguro N, et al. Involvement of choline transporter-

1008 like proteins, CTL1 and CTL2, in glucocorticoid-induced acceleration of

- phosphatidylcholine synthesis via increased choline uptake. Biol Pharm Bull2010;
- 1011 106. Wilk JB, Shrine NRG, Loehr LR, et al. Genome-wide association studies identify
- 1012 CHRNA5/3 and HTR4 in the development of airflow obstruction. Am J Respir
- 1013 Crit Care Med 2012;
- 1014 107. Lam DCL, Luo SY, Fu KH, et al. Nicotinic acetylcholine receptor expression in
  1015 human airway correlates with lung function. Am J Physiol Lung Cell Mol
  1016 Physiol 2016;
- 1017 108. Oenema TA, Kolahian S, Nanninga JE, et al. Pro-inflammatory mechanisms of

1018		muscarinic receptor stimulation in airway smooth muscle. Respir Res 2010;
1019	109.	Yamada M, Ichinose M. The cholinergic pathways in inflammation: A potential
1020		pharmacotherapeutic target for COPD. Front. Pharmacol. 2018;
1021	110.	Fadason T, Schierding W, Lumley T, O'Sullivan JM. Chromatin interactions and
1022		expression quantitative trait loci reveal genetic drivers of multimorbidities. Nat
1023		Commun 2018;9(1):5198.
1024	111.	Lagoumintzis G, Chasapis CT, Alexandris N, et al. COVID-19 and Cholinergic
1025		Anti-inflammatory Pathway: <em>In silico</em> Identification of an
1026		Interaction between $\alpha$ 7 Nicotinic Acetylcholine Receptor and the Cryptic
1027		Epitopes of SARS-CoV and SARS-CoV-2 Spike Glycoproteins. bioRxiv
1028		[Internet] 2020;2020.08.20.259747. Available from:
1029		http://biorxiv.org/content/early/2020/08/21/2020.08.20.259747.abstract
1030	112.	Gahring LC, Myers EJ, Dunn DM, Weiss RB, Rogers SW. Nicotinic alpha 7
1031		receptor expression and modulation of the lung epithelial response to
1032		lipopolysaccharide. PLoS One 2017;
1033	113.	Wang H, Yu M, Ochani M, et al. Nicotinic acetylcholine receptor $\alpha$ 7 subunit is
1034		an essential regulator of inflammation. Nature 2003;421(6921):384-8.
1035	114.	Pinheiro NM, Santana FPR, Almeida RR, et al. Acute lung injury is reduced by
1036		the a7nAChR agonist PNU-282987 through changes in the macrophage profile.
1037		FASEB J 2017;
1038	115.	Hamano R, Takahashi HK, Iwagaki H, Yoshino T, Nishibori M, Tanaka N.
1039		Stimulation of $\alpha$ 7 nicotinic acetylcholine receptor inhibits CD14 and the toll-like
1040		receptor 4 expression in human monocytes. Shock 2006;
1041	116.	Hasday JD, Dubin W, Mongovin S, et al. Bronchoalveolar macrophage CD14
1042		expression: Shift between membrane- associated and soluble pools. Am J Physiol

1043		- Lung Cell Mol Physiol 1997;
1044	117.	Gori S, Alcain J, Vanzulli S, et al. Acetylcholine-treated murine dendritic cells
1045		promote inflammatory lung injury. PLoS One 2019;
1046	118.	Edwards JM, McCarthy CG, Wenceslau CF. The Obligatory Role of the
1047		Acetylcholine-Induced Endothelium-Dependent Contraction in Hypertension:
1048		Can Arachidonic Acid Resolve this Inflammation? Curr Pharm Des 2020;
1049	119.	Radu BM, Osculati AMM, Suku E, et al. All muscarinic acetylcholine receptors
1050		(M1-M5) are expressed in murine brain microvascular endothelium. Sci Rep
1051		2017;
1052	120.	Kumar PT, Antony S, Nandhu MS, Sadanandan J, Naijil G, Paulose CS. Vitamin
1053		D3 restores altered cholinergic and insulin receptor expression in the cerebral
1054		cortex and muscarinic M3 receptor expression in pancreatic islets of
1055		streptozotocin induced diabetic rats. J Nutr Biochem 2011;
1056	121.	Ali N. Role of vitamin D in preventing of COVID-19 infection, progression and
1057		severity. J. Infect. Public Health. 2020;
1058	122.	CHANGEUX jean-pierre, Amoura Z, Rey F, Miyara M. A nicotinic hypothesis
1059		for Covid-19 with preventive and therapeutic implications. Qeios 2020;
1060	123.	Oakes JM, Fuchs RM, Gardner JD, Lazartigues E, Yue X. Nicotine and the
1061		renin-angiotensin system. Am. J. Physiol Regul. Integr. Comp. Physiol. 2018;
1062	124.	Nct. Pyridostigmine in Severe SARS-CoV-2 Infection.
1063		https://clinicaltrials.gov/show/NCT04343963 2020;
1064	125.	Ahmed H O. COVID-19: Targeting the cytokine storm via cholinergic anti-
1065		inflammatory (Pyridostigmine). Int J Clin Virol 2020;
1066	126.	Gonzalez-Rubio J, Navarro-Lopez C, Lopez-Najera E, et al. Cytokine Release
1067		Syndrome (CRS) and Nicotine in COVID-19 Patients: Trying to Calm the Storm.

1068		Front Immunol 2020;
1069	127.	ahir AMOURA FT. Efficacy of Nicotine in Preventing COVID-19 Infection in
1070		Caregivers (NICOVID-PREV). Natl Libr Med 2020;2:1-8.
1071	128.	Smith JC, Sausville EL, Girish V, et al. Cigarette Smoke Exposure and
1072		Inflammatory Signaling Increase the Expression of the SARS-CoV-2 Receptor
1073		ACE2 in the Respiratory Tract. Dev Cell 2020;
1074	129.	Leung JM, Leung JM, Yang CX, Sin DD, Sin DD. COVID-19 and nicotine as a
1075		mediator of ACE-2. Eur. Respir. J. 2020;
1076	130.	Zureik M, Baricault B, Vabre C, et al. Nicotine-replacement therapy as a
1077		surrogate of smoking and the risk of hospitalization with Covid-19 and all-cause
1078		mortality a nationwide observational cohort study in France. medrxiv 2020;
1079	131.	Margină D, Ungurianu A, Purdel C, et al. Chronic inflammation in the context of
1080		everyday life: Dietary changes as mitigating factors. Int. J. Environ. Res. Public
1081		Health. 2020;
1082	132.	Hadjadj J, Yatim N, Barnabei L, et al. Impaired type I interferon activity and
1083		inflammatory responses in severe COVID-19 patients. Science (80-) 2020;
1084	133.	Ye G, Pan Z, Pan Y, et al. Clinical characteristics of severe acute respiratory
1085		syndrome coronavirus 2 reactivation. J Infect 2020;
1086	134.	Xu XW, Wu XX, Jiang XG, et al. Clinical findings in a group of patients infected
1087		with the 2019 novel coronavirus (SARS-Cov-2) outside of Wuhan, China:
1088		Retrospective case series. BMJ 2020;
1089	135.	Grasselli G, Zangrillo A, Zanella A, et al. Baseline Characteristics and Outcomes
1090		of 1591 Patients Infected with SARS-CoV-2 Admitted to ICUs of the Lombardy
1091		Region, Italy. JAMA - J Am Med Assoc 2020;
1092	136.	Marshall JC, Murthy S, Diaz J, et al. A minimal common outcome measure set

1093	for COVID-19	clinical research.	Lancet Infect.	Dis. 2020;

- 1094 137. Office WHOEMR. Updated clinical management guideline for COVID-19.
- 1095 Wkly. Epidemiol. Monit. 2020;
- 1096 138. Rauch A, Labreuche J, Lassalle F, et al. Coagulation biomarkers are independent
- 1097 predictors of increased oxygen requirements in COVID-19. J Thromb Haemost
- 1098 2020;
- 1099 139. Sahu BR, Kampa RK, Padhi A, Panda AK. C-reactive protein: A promising
- biomarker for poor prognosis in COVID-19 infection. Clin Chim Acta 2020;
- 1101 140. Richardson S, Hirsch JS, Narasimhan M, et al. Presenting Characteristics,
- 1102 Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-
- 110319 in the New York City Area. JAMA [Internet] 2020;323(20):2052–9. Available
- 1104 from: https://doi.org/10.1001/jama.2020.6775
- 1105 141. Thomas T, Stefanoni D, Reisz J, et al. COVID-19 infection results in alterations
- 1106 of the kynurenine pathway and fatty acid metabolism that correlate with IL-6

1107 levels and renal status. medRxiv Prepr Serv Heal Sci 2020;

- 1108 142. Moolamalla STR, Chauhan R, Priyakumar D, Vinod PK. Host metabolic
- 1109 reprogramming in response to SARS-Cov-2 infection. bioRxiv 2020;
- 1110 143. Soliman S, Faris MAIE, Ratemi Z, Halwani R. Switching Host Metabolism as an
  1111 Approach to Dampen SARS-CoV-2 Infection. Ann. Nutr. Metab. 2020;
- 1112 144. Frankenberger M, Sternsdorf T, Pechumer H, Pforte A, Ziegler-Heitbrock HWL.
- 1113 Differential cytokine expression in human blood monocyte subpopulations: A
- 1114 polymerase chain reaction analysis. Blood 1996;
- 1115 145. Giamarellos-Bourboulis EJ, Netea MG, Rovina N, et al. Complex Immune
- 1116 Dysregulation in COVID-19 Patients with Severe Respiratory Failure. Cell Host
- 1117 Microbe 2020;

- 1118 146. Lamontagne F, Brower R, Meade M. Corticosteroid therapy in acute respiratory
- 1119 distress syndrome. CMAJ. 2013;
- 1120 147. Russell CD, Millar JE, Baillie JK. Clinical evidence does not support
- 1121 corticosteroid treatment for 2019-nCoV lung injury. Lancet. 2020;
- 1122

## 1123 Acknowledgements

1124 The authors thankfully acknowledge Innovation and Technology Park (Supera), the 1125 healthy-participants joining as controls and the positive COVID-19 patients as well as 1126 their families. We grieve for all patients who lost their lives as a result of this pandemic, 1127 including those who provided us with samples to be able to answer scientific questions 1128 and contribute to humanity's eradication of this disease. We also thank Fabiana Rossetto 1129 de Moraes, B.Sc., for the cytometry analysis, Caroline Fontanari, M.Sc., for laboratory 1130 and technical support, the ICU team, and all hospital professionals, especially the 1131 technicians, nurses, physiotherapists, and biomedical personnel, who collaborated on this 1132 work through Hospital Santa Casa de Misericórdia in Ribeirão Preto and Hospital São 1133 Paulo in Ribeirão Preto. We are grateful for the indispensable contribution of the Ribeirão 1134 Preto Municipal Health Department and the employees of the Serviço de Análises 1135 Clínicas (SAC) of the Faculdade de Ciências Farmacêuticas de Ribeirão Preto, USP. We 1136 also thank Professors Victor Hugo Aquino Quintana, Ph.D., Márcia Regina von Zeska 1137 Kress, Ph.D., and Marcia Eliana da Silva Ferreira, Ph.D. for sharing the BSL2 viral 1138 laboratory.

- 1139
- 1140

## 1141 Additional Information

1163

1142	Extended data available in Supplementary Appendixes:
1143	• Supplementary Appendix I - Pathways and list of corresponding genes related to
1144	acetylcholine and arachidonic acid observed in Reactome pathways and Covid-19
1145	biomarkers.
1146	
1147	• Supplementary Appendix II - Report of CEMITool results for the gene co-
1148	expression modular analysis of lung samples from biopsies of Covid-19 and non-
1149	Covid-19 patients.
1150	
1151	• Supplementary Appendix III - Differential gene expression analysis results
1152	between Covid-19-death groups (CV, NCV, CVL and CVH) and Covid-19
1153	samples from patients who underwent glucocorticoid treatment (GC) and not
1154	(non-GC).
1155	
1156	• Supplementary Appendix IV - Betweenness and degree values of genes from
1157	biological network constructed based on the principal co-expression module M1.
1158	
1159	
1160	Funding
1161	Fundação de Amparo a Pesquisa do Estado de São Paulo (FAPESP):
1162	#2020/05207-6, #2014/07125-6 and #2015/00658-1 for L.H.F.; #2020/08534-8 for

M.M.P.; #2018/22667-0 for C.O.S.S.; #2020/05270-0 for V.D.B. Additional support was

provided by the National Council for Scientific and Technological Development (CNPq),
the Coordination for the Improvement of Higher Educational Personnel (CAPES-Finance
Code 001)), and Pró-Reitora de Pesquisa da Universidade de São Paulo, grant-USPVIDA.

- 1168 **Conflict of Interest Statement**
- 1169 The authors declare that this research was performed without conflicts of interest 1170 or commercial or financial gains.
- 1171 Legends of main figures

Figure 1. Metabolomic and lipidomic analysis revealed increased levels of
circulating fatty acids, arachidonic acid (AA), 5-HETE and 11-HETE in patients
with Covid-19.

1175 Plasma samples were collected from healthy-participants (n=20) and patients with asymptomatic-to-mild (n=10), moderate (n=12), severe (n=16), or critical (n=13) disease. 1176 1177 (A) A Manhattan plot for the differential abundance of metabolite features in different groups of patients with Covid-19 and healthy participants (false discovery rate (FDR) of 1178 1179 595, adjusted P<0.05, above the dashed line) and (B, left panel) metabolic pathway 1180 enrichment of significant metabolite features based on data from untargeted mass 1181 spectrometry. Differential abundance was calculated using the *limma* package for R, and 1182 FDR was controlled using the Benjamini-Hochberg method. Mummichog software v2.3.3 1183 was used for pathway enrichment analysis. (B, right panel) Schematic illustration of the 1184 metabolic pathways involved in the production of hydroxyeicosatetraenoic acids 1185 (HETEs), such as 5-HETE and 11-HETE, from arachidonic (AA) and linoleic acid 1186 metabolism, which discriminate the severity of Covid-19. (C-E) Plasma metabolomics

indicating an increase in free fatty acids in Covid-19. Plasma obtained from healthy participants (n=18) and patients with asymptomatic-to-mild (n=10), moderate (n=12), severe (n=14), or critical (n=16) disease (F-H) was subjected to lipidomics analysis using targeted mass spectrometry, confirming the elevation of AA, 5-HETE and 11-HETE, according to the severity of Covid-19. Data are expressed as the mean  $\pm$  SEM. Differences in (C-H) were considered significant at P<0.05 according to Kruskal–Wallis analysis followed by Dunn's posttest, and specific P-values are shown in each figure.

1194

## 1195 Figure 2. Systemic markers of inflammation determined Covid-19 severity.

1196 (A-F) Total and differential leukocyte counts in peripheral blood from healthy-1197 participants (n=17) and from patients with asymptomatic-to-mild (n=10), moderate 1198 (n=12), severe (n=16) or critical (n=13) disease showed that Covid-19 modified the 1199 numbers of distinct leukocyte populations. (G-H) Flow cytometry analysis of 1200 CD14<sup>+</sup>HLA-DR circulating monocytes by t-distributed stochastic neighbour embedding 1201 indicated reduced (G) CD14 and (H) CD36 mean fluorescence intensity in asymptomatic-1202 to-mild (n=16), moderate (n=15), severe (n=35), and critical (n=20) Covid-19 patients 1203 compared to healthy participants (n=12). (I) Soluble CD14 (sCD14), as determined by 1204 ELISA) in healthy participants (n=12), asymptomatic-to-mild (n=12), moderate (n=13), 1205 severe (n=15), and critical (n=15) patients, showed increases only in samples from critical 1206 Covid-19 patients. (J-L) Classical, intermediate, and nonclassical monocytes determined by flow cytometry analyses of CD14, CD16 and HLA-DR expression in blood cells from 1207 1208 healthy participants (n=12), asymptomatic-to-mild (n=16), moderate (n=15), severe (n=35), and critical (n=20) Covid-19 patients revealed a decrease in intermediate 1209 1210 monocytes in Covid-19. (M-O) Cytokines (IL-8, IL-6, IL-1B, TNF and IL-10) quantified

1211	in plasma using a Cytometric Bead Array (CBA) of healthy volunteers (n=35),
1212	asymptomatic-to-mild (n=29), moderate (n=35), severe (n=42), and critical (n=21)
1213	patients demonstrated a distinct cytokine profile according to disease severity. Data are
1214	expressed as the mean $\pm$ SEM, and differences between groups were calculated using
1215	Kruskal-Wallis with Dunn's multiple comparison post-tests. The specific P-values are
1216	displayed in each figure. Differences were considered significant at $P < 0.05$ .

1217

## Figure 3. Altered production of lipid mediators and cellular infiltrates in the lungs drove the local response to SARS-CoV-2 infection.

1220 BAL was collected from intubated patients with severe/critical confirmed Covid-1221 19 diagnosis and from intubated patients without SARS-CoV-2 infection, which are 1222 labelled as Covid-19 and non-Covid-19, respectively. Data from untargeted mass 1223 spectrometry demonstrated (A) differential abundance of metabolite features comparing 1224 Covid-19 and non-Covid-19 participants (Manhattan plot, 595 at FDR adjusted P<0.05, 1225 above the dashed line) and (B) metabolic pathway enrichment of significant metabolite 1226 features. Differential abundance was calculated using the *limma* package for R, and the 1227 false discovery rate was controlled using the Benjamini-Hochberg method; Covid-19 (n=26) and non-Covid-19 (n=12). Mummichog software v2.3.3 was used for lipid 1228 1229 pathway enrichment analysis. (C) Lipid mediators derived from arachidonic acid (AA) 1230 metabolism by lipoxygenase (LOX) or cyclooxygenase (COX) in both Covid-19 (n=19) 1231 and non-Covid-19 (n=11) samples, as determined by target mass spectrometry, showed a 1232 significant increase in 5-HETE and 11-HETE in Covid-19. (D) Total leukocytes in BAL 1233 fluid (left panel) and a representative image of Romanowsky staining in these cells (right 1234 panel) used for (E) identification of specific cellular populations in Covid-19 (n=23) and

1235 non-Covid-19 (n=11) patients showed a similar profile of infiltrating cells. (F) Cytokine 1236 concentrations in BAL from intubated Covid-19 patients (n=23) and non-Covid-19 1237 participants (n=11) also revealed a similar profile. (G, H) Classical and intermediate 1238 monocytes determined by flow cytometry analyses of CD14, CD16 and HLA-DR 1239 expression in BAL cells from Covid-19 (n=10) and non-Covid-19 (n=11) patients 1240 demonstrate that both populations are decreased in Covid-19. (I) CD14 and (J) CD36 1241 mean fluorescence intensity (MFI) of CD14<sup>+</sup>HLA-DR gated BAL monocytes is 1242 decreased in Covid-19 (n=10) compared to non-Covid-19 (n=11) patients. 5-HPETE: 5-1243 hydroperoxyeicosatetraenoic acid, LTA4: leukotriene A4, LTA4 hydrolase: leukotriene A4 1244 hydrolase, LTB<sub>4</sub>: leukotriene B<sub>4</sub>, 6-trans LTB<sub>4</sub>: 6-trans leukotriene B<sub>4</sub>, 5-HETE: 5hydroxyeicosatetraenoic acid, 11-HETE: 11-hydroxyeicosatetraenoic acid, 12-HETE: 1245 1246 12-hydroxyeicosatetraenoic acid, 15-HETE: 15-hydroxyeicosatetraenoic acid, 5-oxo-1247 HETE: 5-oxoeicosatetraenoic acid, 12-oxo-ETE: 12-oxoeicosatetraenoic acid, 15-oxo-1248 HETE: 15-oxoeicosatetraenoic acid, PGH<sub>2</sub>: prostaglandin H<sub>2</sub>, PGE<sub>2</sub>: prostaglandin E<sub>2</sub>, 1249 PGD<sub>2</sub>: prostaglandin D<sub>2</sub>, TXB<sub>2</sub>: thromboxane B, TX synthase: thromboxane. Data are 1250 expressed as the mean  $\pm$  SEM. Differences between groups were calculated using the 1251 Mann-Whitney test, and specific P-values are shown in the figure. Differences were 1252 considered significant at P<0.05.

1253

Figure 4. Severe and critical phases of Covid-19 correlated with increased systemic and lung acetylcholine and lipid mediators, but only ACh was diminished by glucocorticoids

1257 Comparison of systemic and local lung responses was analysed using blood and
1258 BAL samples from patients with severe/critical Covid-19 and showed that among (A)

1259	cytokines (plasma n=9; BAL n=9), (B) AA (plasma n=29; BAL n=19), (C) 5-HETE
1260	(plasma n=29; BAL n=19), and (D) 11-HETE (plasma n=29; BAL n=19), levels of only
1261	AA were higher in blood. (E) The ACh concentration (pmol.mL <sup>-1</sup> ) in heparinized plasma
1262	from healthy-participants (n=6) compared to plasma from SARS-CoV-2-infected patients
1263	not treated with glucocorticoids (non-GC) classified as having asymptomatic-to-mild
1264	(n=5), moderate (n=9), severe (n=7), and critical (n=7) disease showed an increase based
1265	on disease severity. (F) ACh in the plasma of patients with Covid-19 at severe/critical
1266	stages of the disease and treated (GC, n=18) or not (non-GC, n=14) with glucocorticoids
1267	shows decreased release in response to the treatment. (G) Comparison of ACh in BAL
1268	from SARS-CoV-2-infected severe/critical patients treated (CG, n=17) or not (non-GC,
1269	n=3) with glucocorticoids confirmed inhibition of the neurotransmitter by the treatment.
1270	(H) Comparison of neutrophil numbers from blood (n=14) and BAL (n=14) of patients
1271	with severe/critical disease demonstrated increased neutrophil infiltration in the lungs.
1272	Data are expressed as the mean $\pm$ SEM. Differences were considered significant at P<0.05
1273	according to (A) and (E) Kruskal-Wallis tests followed by Dunn's posttest. (B, C, D, F
1274	and G) Student's t-tests, Mann-Whitney, (H) Wilcoxon matched-pairs signed rank test.
1275	Concentrations of ACh in the blood of patients with severe and critical disease and not
1276	treated with glucocorticoids were the same, as shown in panels (E) and (F). Blood and
1277	BAL were collected during hospitalization, on average 6 to 17 days after admission, and
1278	glucocorticoids (methylprednisolone; range 40 to 500 mg/kg/day, or dexamethasone;
1279	range 1.5 to 6.0 mg/kg/day) were administered intravenously. Interaction networks
1280	between various pairs of mediators quantified in (I) blood (n=151) or (J) BAL (n=32)
1281	from our Covid-19 cohort, as constructed using the open access software Cytoscape v3.3
1282	(Cytoscape Consortium, San Diego, CA) and Spearman tests and showing significant
1283	correlations depicted by different lines (r and P values described in section 7.1). (K-P)

1284 Venn diagram constructed according to the online tool Draw Venn Diagram 1285 (http://bioinformatics.psb.ugent.be/webtools/Venn/) illustrates high-producing patients 1286 in severe and critical stages of disease, with (GC) or without (non-GC) treatment. (K-N) 1287 Plasma from patients producing high levels of AA, 5-HETE, 11-HETE, ACh and sCD14 1288 in GC (n=49) or non-GC (n=17) groups. (O, P) BAL from patients producing high levels 1289 of AA, 5-HETE, 11-HETE, and ACh in GC (n=23) or non-GC (n=4) groups. For analysis, 1290 the global median between controls and patients was considered as the cut-off point. (Q) 1291 Summary data of the values used for construction of the Venn diagrams. The table shows 1292 the absolute number of patients present at each stage of the disease and whether 1293 glucocorticoids were used for each molecule analysed. The percentage of individuals 1294 present in each experimental condition is highlighted in brackets.

1295

# Figure 5. Re-analysis of transcriptome data reinforced the correlation between acetylcholine and arachidonic acid to Covid-19 severity and mortality.

1298 (A) Gene coexpression profile from CVL, CVH, and NCV samples in principal 1299 module M1 (1047 genes, red lines) and mean gene expression (black line) (n=51). Genes 1300 identified as being associated with AA and ACh were only found in module M1; ten are 1301 related to cholinergic receptors and the ACh release cycle and eight to AA metabolism 1302 along with several biomarkers related to Covid-19 severity (Supplementary Appendix II; 1303 Table S4). (B) Heatmap of normalized gene expression related to the ACh and AA 1304 pathways and Covid-19 biomarkers (n=51). Almost all coexpressed genes of the ACh and 1305 AA pathways were upregulated in the CVL versus CVH group, including twelve 1306 cholinergic receptors, six ACh release cycle genes, eighteen AA production and 1307 metabolism pathway genes, and nine eicosanoid receptors (Figure S6A; Supplementary

1308 Appendix III). Approximately 36% of these genes were also upregulated in the CVL 1309 versus NCV group but not in the CV versus NCV group (n=51); among them, elongation of very long-chain fatty acid protein 2 (ELOVL2) is involved in linoleic acid metabolism 1310 1311 (Figure S6A; Supplementary Appendix III). Cases 3, 9, and 11 were glucocorticoid-1312 treated patients. (C) First-order gene interaction network of the M1 module containing 1313 differentially expressed genes related to ACh (brown), AA (green), Covid-19 biomarkers 1314 (red), betweenness hubs (blue), and albumin genes (magenta - Covid-19 biomarker and 1315 hub). Ten DEGs related to ACh and ten DEGs of AA populated the biological network 1316 and are connected to thirteen genes involved in the pathophysiology of Covid-19 and 1317 CD36. ACh- and AA-related genes showed relatively low values of centrality metrics and 1318 may be under the action of some hub genes, such as oestrogen receptor II (ESR2), insulinlike growth factor II mRNA binding protein (IGF2BP1), albumin (ALB), and others 1319 1320 (Supplementary Appendix IV). (D) Plasma and BAL levels of ACh (n=52). ACh levels 1321 in BAL fluid exhibited a tendency towards increase compared to plasma samples from 1322 deceased or discharged patients. (E) AA (n= 48) and AA concentrations were higher in 1323 plasma than in BAL in both patient groups. (F) 5-HETE (n=48) and (G) 11-HETE (n=47) 1324 in several/critical patients according to outcome (discharged or deceased). 5-HETE and 1325 11-HETE levels were only significantly higher in the BAL of deceased patients. (H) 1326 Transcription levels of cholinergic muscarinic M3 receptor (CHRM3) and cholinergic 1327 receptor nicotinic alpha 7 (CHRNA7) (n=51) and (I) oxoeicosanoid receptor 1 (OXER1) (n=51). A unique gene expression profile in lung samples from Covid-19 patients who 1328 1329 had died was characterized by high levels of pro-inflammatory cholinergic receptors (CHRM3, CHRNA3, and CHRNA5) 9,110, low levels of anti-inflammatory cholinergic 1330 1331 receptor (CHRNA7)<sup>113</sup>, and high expression of oxoeicosanoid receptor 1 (OXER1)<sup>50</sup> 1332 which mediates the pro-inflammatory effects of eicosanoids (Figures S6B, S6C). Other

1333	eicosanoid and cholinergic receptors were also differentially expressed in CVL patients
1334	compared to the CVH or NCV group (Figures S6A, S6B, S6C). Finally, transcriptome
1335	analysis of fifteen Covid-19 and five non-Covid-19 samples indicated a correlation
1336	between ACh and AA genes and Covid-19 severity in some CVL patients. Significant
1337	differences in BAL/plasma levels of mediators were set at P< $0.05$ according to the
1338	Kruskal-Wallis test followed by Dunn's posttest. *present in module M1. Abbreviations:

1339 Covid-19 low viral load (CVL) - Covid-19 high viral load (CVH) - non-Covid-19 (NCV).



Figure 1









## 1342

Figure 3



Page 59 of 84



```
Figure 4
```





#### 1345 **Supplementary Tables**

#### 1346 Table S1 – Classification of study participants

Participant's classification	Symptoms, signs, and parameters
Group 1 Healthy-participants	<ul><li>Negative for SARS-Cov-2 nucleicacid</li><li>No clinical signs</li></ul>
Group 2 Asymp-to-mild	<ul> <li>Positive for SARS-Cov-2 nucleic acid and/or serological test</li> <li>With or without the following symptoms: diarrhea, cough, fever, headache, loss of taste (ageusia)/smell (anosmia), myalgia, nausea, and vomiting</li> </ul>
Group 3 <b>Moderate</b>	<ul> <li>Oxygen saturation 94-99 % on room air</li> <li>Positive for SARS-Cov-2 nucleic acid and/or serological test</li> <li>Manifestation of mild disease symptoms including dyspnea</li> <li>Oxygen saturation ≥93% on room air</li> <li>PaO<sub>2</sub>/FiO<sub>2</sub> 250-300mmHg</li> <li>Do not need invasive ventilation: nasal catheter (oxygen 2-4L/min) or oxygen reservoir (oxygen 4-10L/min)</li> </ul>
Group 4 <b>Severe</b>	<ul> <li>Positive for SARS-Cov-2 nucleic acid and/or serological test</li> <li>Admission to intensive-care units</li> <li>Severe respiratory distress</li> <li>Oxygen saturation &lt;93% on room air</li> <li>PaO<sub>2</sub>/FiO<sub>2</sub> &lt;250mmHg</li> <li>Need no-invasive ventilation: oxygen reservoir or non-rebreathing face mask (oxygen 10-15L/min).</li> </ul>
Group 5 <b>Critical</b>	<ul> <li>Positive for SARS-Cov-2 nucleic acid and/or serological test</li> <li>Admission to intensive-care units</li> <li>Acute respiratory distress syndrome</li> <li>Need invasive ventilation</li> <li>PaO<sub>2</sub>/FiO<sub>2</sub> &lt;200mmHg</li> <li>With or without one or more additional parameters: need hemodialysis, sepsis, septic shock, and multiorgan dysfunction</li> </ul>

1347

1348 The participants were classified into five clinical groups (G1–G5): healthy participants (G1) and 1349 Covid-19 patients (G2 to G5), based on the severity of disease, clinical parameters, patient's 1350 management, and laboratory findings, following the recommendations from WHO <sup>132–137</sup>. These 1351 classifications were used to define the scale of the clinical progression of patients. The inclusion 1352 criteria were as follows: (i) signed informed consent form; (ii) fit into one of the five clinical 1353 groups; (iii) healthy participants must be negative for SARS-CoV-2 nucleic acid; (iv) 1354 asymptomatic or symptomatic participants must be positive for SARS-CoV-2 nucleic acid and/or 1355 anti-SARS-CoV-2 antibody; (v) age  $\geq 12$  years. Participants from groups G1, G2, and G5 were 16

- 1356 years old or older, while the participants from groups G3 and G4 were 12 years old or older.
- 1357 Pregnancy was the only exclusion criterion for healthy participants (G1). Abbreviations: FiO<sub>2</sub>,
- 1358 fraction of inspired oxygen; PaO<sub>2</sub>, partial pressure of oxygen.

1359

	Healthy-	All motion to	COVID-19 care					
<b>Baseline Variable</b>	participants N= 39	All patients N= 190	Asym-to-mild N= 43	Moderate N- 44	Severe N- 54	Critical N= 49	P value (§)	
Demographic characteristics			- +3	N= <del>11</del>	11-34	11- 12		
<u>_</u>	36±16.06	53±18.42	39± 10.74	47± 16.90	62± 15.88	66± 16.63		
Age median $\pm$ SD, (IQR)	(23-80)	(16-96)	(20-57)	(16-92)	(30-96)	(20-86)	<0.001	
Gender, No. (%)	. ,	. ,				. ,		
Male	19 (49)	107 (56)	18 (42)	25 (57)	30 (56)	34 (69)		
Female	20 (51)	83 (44)	25 (58)	19 (43)	24 (44)	15 (31)	- 0.400	
Comorbidities or coexisting disorders, No. (%)								
Hypertension	5 (13)	77 (41)	5 (12)	11 (25)	40 (74)	21 (43)	<0.001	
Dyslipidemia	8 (21)	28 (15)	7 (16)	8 (18)	8 (15)	5 (10)	0.102	
Diabetes mellitus	1 (3)	51 (27)	3 (7)	11 (25)	25 (46)	12 (24)	0.002	
Obesity	5 (13)	36 (19)	8 (19)	11 (25)	8 (15)	9 (18)	0.450	
Neurological Disease	-	20 (11)	-	3 (7)	8 (15)	9 (18)	-	
Respiratory Disorders	1 (3)	34 (18)	12 (28)	10 (23)	3 (6)	9 (18)	<0.001	
Symptoms, No. (%)								
Dyspnea	-	103 (54)	3 (7)	35 (80)	36 (67)	29 (59)	-	
Fever	-	57 (30)	1 (2)	10 (23)	26 (48)	20 (41)	-	
Myalgia	-	40 (21)	-	8 (18)	19 (35)	13 (27)	-	
Diarrhea	-	48 (25)	13 (30)	13 (30)	13 (24)	9 (18)	-	
Cough	-	127 (67)	25 (58)	34 (77)	41 (76)	27 (55)	-	
Anosmia	-	59 (31)	27 (63)	19 (43)	7 (13)	6 (12)	-	
Dysgeusia	-	57 (30)	25 (58)	19 (43)	8 (15)	5 (10)	-	
Headache	-	13 (7)	-	4 (9)	5 (9)	4 (8)	-	
Laboratory findings, median ± SD, (IQR)								
Emithmonister (1091-1)	4.7±0.48	4.4±0.88	4.8±0.46	4.5±0.71	4.4±0.99	3.7±0.67	0.0034	
Erythrocytes (TO* L *)	(4.0-5,8)	(1.1 <del>-</del> 5.9)	(3.9-5.9)	(2.9 <del>-</del> 5.9)	(1.1 <del>-</del> 5.9)	(2-5.8)	0.0034	
Hemoglobin (g dl <sup>-1</sup> )	15.0±1.55	13.1±2.68	14.5±1.28	13.9±2.26	12.9±2.64	10.7±2.65	0.001	
Hemoglobin (g dL )	(11.3-17.5)	(6.5-18.2)	(12.0-18.2)	(8.4-18.2)	(6.8-17.6)	(6.5-18.2)	0.001	
Loukocytos $(10^9 L^{-1})$	7.5±1.71	8.8±5.24	7.3±2.28	7.7±2.82	8.6±5.23	13.2±6.00	0.042	
	(4.1-11.2)	(1.6-33.0)	(3.2-13.6)	(2.6-14.9)	(1.6-33.0)	(5.2-29.0)	0.042	
Neutrophils $(10^9 I^{-1})$	4.2±0.99	6.3±4.90	4.1±1.76	4.9±2.72	6.8±4.31	11.4±5.36	<0.001	
	(2.4-6.0)	(1.6-26.1)	(1.6-9.9)	(1.8-13.4)	(0.24-25.1)	(3.7-26.1)	(0.001	
l ymphocytes (10 <sup>9</sup> l <sup>-1</sup> )	2.5±0.85	1.4±0.93	2.3±0.67	2.0±0.90	1.1±0.82	0.9±0.54	<0.001	
	(1.2-5.1)	(0.1-4.3)	(1.2-4.3)	(0.3-4.2)	(0.1-4.1)	(0.2-2.6)		
RNL	1.8±0.56	5.1± 14.93	1.7±0.62	3±5.61	6.6±18.23	11.9±18.30	<0.001	
	(1-3.1)	(0.6 <b>-</b> 115.4)	(0.7-3.6)	(0.6 <del>-</del> 29.7)	(1.3-115.4)	(3.4-92)	(0.001	
Monocytes (10 <sup>9</sup> L <sup>-1</sup> )	0.5±0.17	0.5±0.38	0.5±0.17	0.4±0.23	0.5±0.45	0.5±0.52	0.207	
	(0.3-0.9)	(0.0-2.6)	(0.3-0.9)	(0.1-1.2)	(0.0-2.0)	(0.0-2.6)	0.207	
Platelets (10 <sup>9</sup> L <sup>-1</sup> )	216±37.34	236± 93.69	227±67.10	234± 88.93	251± 108.5	234±98.67	0.039	
· · ·	(129-297)	(50-635)	(135-474)	(117-515)	(85-635)	(50-620)		
Glycemia (mg dL <sup>-1</sup> )	90±10.14	113.5±70.37	88±72.88	99.5±39.38	142±78.65	147.5±59.90	<0.001	
	(76-113)	(28-479)	(65-479)	(65-262)	(28-409)	(76-301)		

	26.0±2.49	26.7±5.65	26.2±3.28	26.6±4.80	27.8±3.66	26.7±9.38		
TTPa (seconds)	(21.8-31.7)	(0.0-64.1)	(20.4-38.6)	(18.2-41.4)	(20.5-35.2)	(0.0-64.1)	0.167	
TD (as as a da)	13.6±1.68	13.1±2.1	13.3±1.29	13.2±1.17	12.6±2.65	13.3±2.81	0.041	
TP (seconds)	(12.6-21.7)	(0.0-18.1)	(12.1-17.5)	(11.0-15.2)	(0.0-15.7)	(0.0-18.1)	0.041	
	1.12±0.17	1.1±0.16	1.1±0.13	1.1±0.10	1.1±0.11	1.2±0.25	0.100	
INR	(1.0-1.97)	(0.0-1.6)	(1.0-1.5)	(0.9-1.4)	(1.0-1.4)	(0.0-1.6)	0.106	
Hospital support, No. (%)								
Infirmary	-	73 (38)	-	20 (45)	50 (93)	3 (6)	-	
Intensive care unit (ICU)	-	53 (28)	-	3 (7)	4 (7)	46 (94)	-	
Hospitalization data, No.								
Hospitalization days, median (IQR)	-	10 (1 24)	-	2 (1 22)	0 (1 22)	14 (4 24)		
Infection data median + SD (IOP)		10 (1-34)		2 (1-23)	9(1-22)	14 (4-34)		
Infection data, median ± 50, (iQR)		E + 2 74		E+2.54	512.07	E + 2 E 9		
Infection days	-	$5\pm 2.74$	-	5±2.54	5±2.97	5±2.58		
Respiratory support received (%)		(1-10)		(1-10)	(2-16)	(1-10)		
		FQ (21)		10 (41)	20 (70)	2 (4)		
Nasal-Cannula Oxygen	-	58 (51)	-	18 (41)	38 (70)	2 (4)	-	
Non-rebreathing mask / Non-invasive ventilation	-	21 (11)	-	-	15 (28)	6 (12)	-	
Invasive mechanical ventilation	-	41 (22)	-	-	1 (2)	40 (82)	-	
Oxygen saturation median $+$ SD (IOR)	98.0±2,16	94.0±11,00	98.0±1.79	97.0±4.40	90.5±15.3	91.5±9.84	<0.001	
	(90-99)	(86-100)	(93-99)	(80-100)	(86-99)	(66-99)		
Denouement, No (%)								
Discharge	-	61 (32.1)	-	20 (45.5)	32 (59.3)	9 (18.4)	-	
Death	-	65 (34.2)	-	3 (6.8)	22 (40.7)	40 (81.6)	-	
Medications No. (%)								
Dexamethasone	-	100 (53)	-	14 (32)	45 (83)	41 (84)	-	
Azithromycin	-	98 (52)	1 (2)	18 (41)	52 (96)	28 (57)	-	
Ceftriaxone	-	110 (58)	13 (30)	17 (39)	50 (93)	30 (61)	-	
Oseltamivir	-	64 (34)	-	4 (9)	37 (69)	23 (47)	-	
Cloroquine/Hydroxycloroquine	-	33 (17)	-	3 (7)	13 (24)	17 (35)	-	
Anticoagulant	1 (3)	4 (2)	1 (2)	-	-	3 (6)	-	
Ivermectin	-	2 (1)	-	1 (2)	1(2)	-	-	

1362

1363 1364

1365

Abbreviations: N, number of participants; SD, standard deviation; IQR, interquartile; RNL, ratio between neutrophils and lymphocytes; N

(%); TTPa, activated partial thromboplastin time; TP, prothrombin time; INR, international normalised ratio. §Comparison of the control

group (healthy participants) with all patients. The values were compared using the  $\chi^2$  test and one-way analysis of variance (ANOVA),

1366 Mann-Whitney test, and nonparametric t-tests for continuous variables. *p*<0.05 was considered statistically significant.

#### 1367 Table S3 - Demographic, clinical characteristics and blood findings data from

### severe/critical participants of which bronchoalveolar lavage (BAL) were collected 1368

#### 1369 (n=45)

Baseline Variable BAL	non-Covid-19 Patients N= 13	Covid-19 N= 32	p Value (§)
Demographic characteristics			
Age median $\pm$ SD, (IQR)	61±21.2 (20-82)	66.5±17 (25-86)	0,4237
Gender, No. (%)			
Male	4 (30,8)	21 (65.6)	-
Comorbidities or coexisting disorders.	9 (09,2)	11 (4.4)	-
Hypertension	4 ( 30.77)	16 (51.61)	0,2052
Dyslipidemia	-	2 (6.45)	-
Diabetes mellitus	2 ( 15.38)	8 (25.81)	0,4517
Obesity	1 (7.69)	3 (9.68)	0,8345
Neurological	2 ( 15.38)	4 (12.90)	0,8268
Presenting symptoms No. (%)	7 (53.85)	3 (9.88)	0,0014
Dyspnea	4 (30.8)	18 (58.1)	
Fever	-	14 (45.2)	-
Myalgia	-	10 (32.3)	-
Diarrehea		7 (22.6)	-
Cough	-	18 (58.1)	-
Hyperactive Delirium	-	-	-
Anosmia	-	4 (12.9)	-
Astemia		3 (9.7)	-
Laboratory findings, median ± SD, (IQ	R)		
Erythrocytes (10 <sup>12</sup> L <sup>-1</sup> )	2.7±0.94 (1.6-5.2)	3.5±0.70 (2-5.3)	0,0175
Hemoglobin (g dL <sup>-1</sup> )	8.7±2.93 (4.6-15.2)	10.3±2.19 (6.5-16.2)	0,0319
Leukocytes (10 <sup>9</sup> L <sup>-1</sup> )	11.5±15.44 (7.8-62.4)	11.8±6.70 (4.6-29.0)	0,7848
Neutrophils (10 <sup>9</sup> L <sup>-1</sup> )	8.6±11.18 (4.5-45.5)	9.6±5.95 (3.3-26.1)	0,9842
Lymphocytes (10 <sup>9</sup> L <sup>-1</sup> )	1.2±1.08 (0.3-4.4)	0.9±0.54 (0.4-2.2)	0,2127
RNL	7±21.15 (2.6-73)	11.0±10.05 (3.36-43.5)	0,2925
Monocytes (10 <sup>9</sup> L <sup>-1</sup> )	0.6±0.51 (0.3-1.8)	0.6±0.55 (0-2.6)	0,5627
Platelets (10 <sup>9</sup> L <sup>-1</sup> )	254±165.8 (71-553)	252±86.8 (50-414)	0,4519
Glycemia (mg dL <sup>-1</sup> )	151.5±85.91 (9.8-376)	148±58.23 (76-300)	0,5848
TP	13.2±1.97 (11.5-17.1)	13.1±3.34 (0-18.1)	0,8464
ТТРа	25.5±6.30 (22.6 <b>-</b> 46)	25.2±10.96 (0 <b>-</b> 64.1)	0,6380
INR Bespiratory support received (%)	1.1±0.18 (0.1-1.5)	1.2±0.30 (0-1.6)	0,9632
Oxygen Saturation median ± SD (IQR)	94±6.41 (78-100)	91±10.36 (66-99)	0.0500
Hospitalization data, No.			0,0500
Hospitalization days, median (IQR)	22±11.41 (6-43)	14±15.36 (5-34)	0.0888
Infeccions data, median ± SD, (IQR)			0,0000
Infection days	4±3.27 (2-10)	6±2.46 (0-11)	0,3166
Denouement, No (%)			
Discharge	9 (69.2)	4 (12.9)	-
Death	4 (30.8)	28 (87.5)	-
Medications No. (%)	2 (15 20)	26 (02 07)	
Dexamethasone	2 (15.38)	26 (83.87)	< 0,0001
Ceftriaxone	10 (76.92)	25 (78.13)	0.9300
Oseltamivir	1 (7.69)	16 (51.61)	0,0063
Cloroquine/Hydroxycloroquine	1 (7.69)	10 (32.26)	0,0860
Anticoagulant	-	-	-
vermectin	-	-	-

1370

1371	Abbreviations: N, number or values; SD, standard deviation; IQR, minimum and maximum
1372	values; RNL, ratio between neutrophils and lymphocytes; N (%); TTPa, activated partial
1373	thromboplastin time; TP, prothrombin time; INR, international normalised ratio. §Comparison of
1374	the Covid-19 negative patients group with Covid-19 positive patients. The values were compared
1375	using the $\chi^2$ test and one-way analysis of variance (ANOVA), Mann-Whitney test, and
1376	nonparametric t-tests for continuous variables. $p < 0.05$ was considered statistically significant.

1377

#### Table S4 - List of genes related to acetylcholine and arachidonic acid 1378

1379

## pathways and Covid-19 biomarkers founded in co-expression module M1

Gene (symbol)	Gene (name)	Pathway or Biomarker
CHRM2	cholinergic receptor muscarinic 2	
CHRM3	cholinergic receptor muscarinic 3	
CHRM5	cholinergic receptor muscarinic 5	
CHRNA2	cholinergic receptor nicotinic alpha 2 subunit	
CHRNA3	cholinergic receptor nicotinic alpha 3 subunit	
CHRNA4	cholinergic receptor nicotinic alpha 4 subunit	Acetylcholine
CHRNA5	cholinergic receptor nicotinic alpha 5 subunit	
CHRNB2	cholinergic receptor nicotinic beta 2 subunit	
PPFIA4	PTPRF interacting protein alpha 4	
RIMS1	regulating synaptic membrane exocytosis 1	
ALOX15	arachidonate 15-lipoxygenase	
CYP4F3	cytochrome P450 family 4 subfamily F member 3	
CYP4A11	cytochrome P450 family 4 subfamily A member 11	
CYP8B1	cytochrome P450 family 4 subfamily B member 1	
CYP4F8	cytochrome P450 family 4 subfamily F member 8	Arachidonic acid
CYP2C8	cytochrome P450 family 2 subfamily C member 8	
CYP1A1	cytochrome P450 family 1 subfamily A member 1	
DPEP2	dipeptidase 2	
ALB	Albumin	
CPP	C-reactive protein	
	C V C motif champleing ligger d	
		Biomarker
FGA	fibrinogen alpha chain	(COVID-19)
FGB	fibrinogen beta chain	
IL1β	interleukin 1 beta	

1380

1381 Co-expression analysis generated five different co-expression gene modules (M1 to 1382 M5) and only in M1 we identified genes that encoding proteins associated to 1383 cholinergic receptors (muscarinic and nicotinic), ACh release cycle, and AA 1384 metabolism. In addition, the M1 module also contains some biomarkers related to

- 1385 Covid-19 severity (albumin, C-reactive protein, IL-8, fibrinogen, and IL1β)

1386 <sup>21,34,138,139</sup>.

- 1387 Table S5 Treatment of severe and critical Covid-19 patients with glucocorticoids
- 1388 does not alter the levels of plasmatic cytokines and circulating neutrophils and
- 1389 lymphocytes

	Severe non-GC N=3	Severe GC N=39	P value (#)	Critical non-GC N=4	Critical GC N=17	P value (§)	
Parameters, me	dian ± SEM, (l	QR)					
II _8	31.7±12.6	26.3±4.97	0 4 5 4	26.86±6.5	113.2±48.8	0 1 4 4	
IL-0	(13.6-56.0)	(2.8-186.4)		(10.2-41.8)	(13.1-661.9)	0.144	
II -6	42.7±20.1	54.9±14.19	0 782	46.4±13.2	317.7	0.410	
IL-0	(4.80-73.2)	(3.3-414.1)	0.782	(24.7-81.7)	±160.3	0.410	
IL-1	2.5±2.5	0.1±0.05	0 104	0.9±0.9	(11.3-2510)	0.874	
	(0.0-7.6)	(0.0-1.7)	0.104	(0.0-3.6)	0.5±0.3		
TNE	0.0±0.0	0.01±0.1	>0.000	0.8±0.8	(0.0-3.8)	0 1 0 1	
INF	(0.0-0.0)	(0.0-0.3)	>0.999	(0.0-3.1)	0.04±0.04	0.191	
II 10	1.0±0.5	2.7±0.4	0 165	2.3±1.1	(0.0-0.7) 7.5	0 220	
IL-IU	(0.4-2.1)	(0.3-9.1)	0.105	(0.8-4.3)	±2.6	0.229	
Noutrophile	56.5±20.8	80.5±1.7	0.007	79.9±3.8	(0.1-45.1)	0 1 0 7	
Neutrophils	(15.0-77.5)	(38.6-97.0)	0.097	(73.1-89.0)	85.6±1.5	0.197	
l y man h a system	9.7±1.6	12.0±0.9	0.400	10.9±2.2	(70.1-93.0)	0 1 5 6	
Lymphocytes	(8.0-13.0)	(2.0-27.8)	0.490	(5.0-14.7)	7.9±1.0	0.150	
DNU	5.7±2.2	10.2±1.6	0.402	9.0±2.7	(4.0-20.5)	0 1 4 0	
KNL	(1.9-9.4)	(2.2-47.5)	0.403	(5.1-16.6)	13.3±1.5	0.140	
					(3.4-23.3)		

1390

Abbreviations: N, number of participants; SEM, standard error of the mean; IQR, interquartile; RNL, ratio between neutrophils and lymphocytes. Comparison of the severe non-GC group withthe severe GC group, and the critical non-GC group with the critical GC group. The values were compared using the  $\chi^2$  test, one-way analysis of variance (ANOVA), Mann-Whitney test, and nonparametric t-tests for continuous variables. *p*<0.05 was considered statistically significant.

As shown in the table, glucocorticoid therapy in severe Covid-19 patients did not show a statistically significant influence on the plasma levels of the cytokines evaluated in our study. The use of glucocorticoids and their impact on the production of inflammatory molecules is closely associated with several factors, such as the dose, duration, and time of initiation of therapy, since,

- 1400 in the critical stages of Covid-19, no beneficial effects of glucocorticoids have been observed in
- 1401 the inflammation control and patient outcome <sup>70,71</sup>.

### 1402 Table S6 - Impact of glucocorticoid therapy in the outcome of hospitalized Covid-

1403 **19 patients** 

	Moderate		Seve	re	Critical		
	N=23		N=54	4	N=49		
No, (%)	Discharge	Death	Discharge	Death	)eath Discharge		
	N=20	N=3	N=32	N=22	l=22 N=9		
non-GC	7 (35)	0 (0)	4 (12.5)	3 (13.6)	4 (44.4)	9 (22.5)	
GC	13 (62)	3 (100)	28 (87.5)	19 (86.4)	5 (55.6)	31 (77.5)	

1404

1405 Abbreviations: N, number of participants (%).

1406 Hospitalised Covid-19 patients from the moderate, severe, and critical groups were administered glucocorticoid (GC) therapy or not (non-GC) (methylprednisolone; range 40 to 500 1407 1408 mg/kg/day, or dexamethasone; range 1.5 to 6.0 mg/kg/day, by intravenous route). Most 1409 hospitalised patients were treated with glucocorticoids (moderate [69.6%], severe [87.0%], and 1410 critical [73.5%]). All moderate non-GC-patients were discharged, while GC patients had a 1411 mortality rate of 18.8%. In addition, the mortality rates for severe-GC (40.4%) and critical-GC 1412 (86.1%) patients were higher than those for moderate-CG patients. The discharge rates of non-1413 GC patients vary according to the clinical categorization (100.0%, 57.1%, and 30.8% for 1414 moderate, severe, and critical, respectively). Hospitalised Covid-19 patients from our cohort 1415 showed fewer benefits of glucocorticoid therapy than those reported in the RECOVERY trial <sup>68</sup>, but similar benefits to those described in the CoDEX trial conducted in Brazil <sup>69</sup>. This reduction 1416 1417 of glucocorticoid benefits could be associated with several factors, including a low mean 1418 PaO<sub>2</sub>:FiO<sub>2</sub> ratio and an overload of the health systems of countries with limited resources, such as Brazil<sup>69</sup>, as well as glucocorticoid dose, initiation, and duration of therapy<sup>70,71</sup>. 1419

1420

#### 1421 Table S7 – Analysis of the potential interference of Covid-19-confounding variables

#### 1422 on the correlation between high plasma levels of cholinergic and lipid mediators and

#### 1423 Covid-19 severity.

Confounding variables	Healthy participants	Asym-to-mild	Moderate	Severe	Critical	P <i>value</i> (§)			
Lipid mediators (AA, 5-HETE, and 11-HETE)									
No	17	10	11	16	11				
Age, mean ( <b>I</b> QR)	33 (27-44)	33 (26-43)	39 (30-48)	57 (48-78)	71 (57-78)	<0.001			
Gender, No (%) Male						0.795			
Female	7 (41.2)	5 (50.0)	6 (54.5)	7 (43.8)	7 (63.6)				
Diabetes, No (%)	10 (58.8)	5 (50.0)	5 (45.5)	9 (56.2)	4 (36.4)				
Hypertension, No (%)	1 (5.9)	1 (10.0)	3 (27.3)	6 (37.5)	2 (18.2)	0.183			
Obesity, No (%)	2 (11.8)	0 (0.0)	0 (0.0)	12 (75.0)	6 (54.5)	<0.001			
	4 (23.5)	2 (20.0)	3 (27.3)	2 (12.5)	1 (9.1)	0.7788			
		ACh			· · ·				
No	6	5	4	6	8				
Age, mean ( <b>I</b> QR)	30 (24-56)	42 (38-46)	48 (39-57)	75 (63-79)	65 (52-74)	0.026			
Gender, No (%) Male						0.290			
Female	4 (66.7)	3 (60.0)	2 (50.0)	1 (16.7)	6 (75.0)				
Diabetes, No. (%)	2 (33.3)	2 (40.0)	2 (50.0)	5 (83.3)	2 (25.0)				
Hypertension, No. (%)	0 (0.0)	1 (20.0)	1 (25.0)	3 (50.0)	1 (12.5)	0.282			
Obesity, No. (%)	2 (33.3)	2 (40.0)	1 (25.0)	5 (83.3)	3 (37.5)	0.360			
	1 (16.7)	1 (20.0)	0 (0.0)	0 (0.0)	2 (25.0)	0.767			

1424

1425 We analysed some confounding variables associated with Covid-19, such as comorbidities (Diabetes 1426 mellitus, hypertension, and obesity) and risk factors (advance age and gender) <sup>51,140</sup>, using data from 1427 participants whose plasma levels of lipid mediators (AA, 5-HETE, and 11-HETE) and ACh were measured. 1428 Lipid mediators data came from Covid-19 patients and heathy participants presented in Figure 1 (Panels: 1429 F, G, and H), while ACh data came from glucocorticoid-non-treated Covid-19 patients presented in Figure 1430 4E. Age and hypertension or only age are potential confounding variables on the correlation between high 1431 plasma levels of lipid mediators or ACh and Covid-19 severity, because (i) age had significant Spearman's 1432 correlation with AA (r=0.36; P=0.0042), 5-HETE (r=0.36; P=0.0042), and ACh (r=0.37; P=0.0485); and 1433 (ii) hypertensive patients had significantly increased plasma levels of AA (p=0.0062 - Mann-Whitney test). 1434 §Kruskal-Wallis or Fisher's tests were used to compare the differences between all clinical categories. Data 1435 are expressed as median (IQR - interquartile range) or number (% - percentages), and P < 0.05 was 1436 considered statistically significant.

## 1437 Table S8 - Analysis of the potential interference of Covid-19-confounding

## 1438 variables on the correlation between high ACh levels in severe/critical

1439 patients, treated or not with glucocorticoids, and Covid-19 severity.

	Severe (Plasm)			Cri	itical (Plasn	n)	Critical (BAL)		
Confounding variabl	es non-GC	GC	P value	non-GC	GC	P value	non-GC	GC	P value
N		10	(9)			(9)		17	(9)
No	6	10		8	8		3	17	
Age, median	75 (63-79)	68 (55-76)	0.415	65 (52-74)	76 (60-79)	0.316	74 (72-80)	62 (53-76)	0.243
(IQR) Gender, No			0.118			1.000			0.920
(%) Male	1 (16.7)	7 (70.0)		6 (75.0)	6 (75.0)		2 (66.7)	11 (64.7)	
Female Diabetes,	5 (83.3)	3 (30.0)		2 (25.0)	2 (25.0)		1 (33.3)	6 (35.3)	
No (%)	4 (40.0)	6 (60.0)	1.000	1 (12.5)	3 (37.5)	0.569	1 (33.3)	3 (17.6)	0.450
Hypertension, No	2 (20.0)	8 (80.0)	1.000	3 (37.5)	5 (62.5)	0.619	3 (100.0)	6 (35.3)	0.073
(%) Obesity, No (%)	0 (0.0)	1 (10.0)	1.000	2 (25.0)	2 (25.0)	1.000	0 (0.0)	3 (17.6)	1.000

1440

1441 Here we used the same confounding variables associated with Covid-19 described on Table 1442 S7. This analysis was based on plasma and BAL cholinergic mediator (ACh) data from 1443 severe/critical Covid-19 patients, treated (GC) or not (non-GC) with glucocorticoids, and 1444 reported in Figure 4 (Panels: F and G). None of the confounding variables tested had significant 1445 potential to interfere with the glucocorticoid-therapy ability to reduce the high plasma and BAL 1446 ACh levels in severe/critical patients. §Mann-Whitney or Fisher's tests were used to compare 1447 the differences between severe and critical clinical categories. Data are expressed as median 1448 (IQR - interquartile range) or number (% - percentages), and P < 0.05 was considered 1449 statistically significant.
#### 1450 Table S9 - Impact of Covid-19 confounding variables on the comparative analysis

### 1451 between high levels of lipid mediators in plasma and BAL samples from severe and

#### 1452 critical patients.

<b>Confounding variables</b>	Severe/Critical (Plasm)	Severe/Critical (BAL)	P value (§)
No	25	18	
Age, median (IQR)	60 (53-77)	64 (52-83)	0.6395
Gender, No. (%) Male			0.1394
Female	14 (56.0)	14 (77.8)	
Diabetes, No. (%)	11 (44.0)	4 (22.2)	
Hypertension, No. (%)	7 (28.0)	5 (27.8)	0.9872
Obesity, No. (%)	16 (64.0)	9 (50.0)	0.3586
	3 (12.0)	4 (22.2)	0.4274

## 1453

1454 We used the same confounding variables associated with Covid-19 reported on Table S7. This 1455 analysis was based on plasma and BAL levels of lipid mediators (AA, 5-HETE, and 11-HETE) 1456 from severe/critical Covid-19 patients reported in Figure 4 (Panels: B, C, and D). None of the 1457 confounding variables tested had significant potential to interfere with the comparison between 1458 altered plasm and BAL levels of lipid mediators in severe/critical patients. §Mann-Whitney, chi-1459 square, or Fisher's tests were used to compare the differences between severe and critical patients. 1460 Data are expressed as median (IQR - interquartile range) or number (% - percentages), and P < 1461 0.05 was considered statistically significant.

# 1462 Supplementary Figures

## 1463 Figure S1 – Metabolic signatures of plasma and BAL samples from patients



1464 infected or not with SARS-CoV-2.

1465

Hierarchical clustering based on different characteristics of abundant metabolites
(ANOVA-FDR <0.1) between controls and patients positive for SARS-CoV-2 at different stages</li>
of the disease in plasma (A) and non-Covid-19 versus Covid-19 BAL patients (B). In (A), the
clinical classification of Covid-19 was: healthy participants (n=20), asymptomatic-to-mild
(n=10), moderate (n=12), severe (n=16), and critical (n=13) groups. In (B), the same analysis was
performed with data from BAL samples of non-Covid-19 (n=12) and Covid-19 (n=26) patients.
The detection levels of metabolites were defined using Z-score normalisation.

1473 The analysis of hierarchical clustering (A) shows highly different metabolomic profiles 1474 in the plasma for each group of individuals according to disease severity. BAL analysis (B) of 1475 samples from Covid-19 patients demonstrated an increase in the abundance of metabolites 1476 compared to non-Covid-19 individuals. The results indicated that SARS-CoV-2 infection induces

changes in the metabolic profile of humans. Our data are in agreement with previous results
showing virus-induced metabolic reprogramming in the host. The increased abundance of
metabolites and their pathways, such as free fatty acids and amino acids, was correlated to the
increase in viral proliferation, since these biomolecules can act as building blocks and fuel for
this process <sup>141–143</sup>.

#### 1482 Figure S2 - Gating strategy used for flow cytometry analysis of monocyte subsets

#### 1483 and CD14/CD36 expression



1485

1486 In (A), dot plots show a representative gating strategy for the analysis of FSC-H/FSC-A, 1487 SSC-A/FVS-620 (viable cells), and SSC-A/FSC-A, followed by CD14<sup>+</sup>HLA-DR<sup>+</sup> monocytes and 1488 the classical (CD14<sup>high</sup>CD16<sup>-</sup>), intermediate (CD14<sup>+</sup>CD16<sup>+</sup>) or non-classical CD14<sup>low</sup>CD16<sup>+</sup> 1489 subsets, with subsequent CD36 mean fluorescence intensity (MFI) in whole blood (upper panel) 1490 and bronchoalveolar lavage fluid (BAL, bottom panel). In (B), a violin plot shows the frequency 1491 of non-classical monocytes from BAL of non-Covid-19 and Covid-19 patients. In (C), CD36 MFI 1492 in classical, intermediate, and non-classical monocytes from BAL of non-Covid-19 and Covid-1493 19 samples. Differences between groups were calculated using the Mann-Whitney test.

All rights reserved.	No reuse allowed without permission.	

1494	The membrane markers and gating strategies used to define the different monocyte
1495	subpopulations in the blood and BAL samples were adapted from a previous publication (ref). In
1496	BAL, there was a tendency to reduce non-classical monocytes in Covid-19 patients compared to
1497	non-Covid-19 patients (Figure 2SB), as well as a decrease in CD36 expression in classical and
1498	intermediate monocytes (Figure 2SC), although the difference was not statistically significant.
1499	Although not significantly, this reduction may have a biological importance. These data are
1500	similar to the profile observed in the blood monocytes of Covid-19 patients (Figure 3J).

#### 1501 Figure S3 - Determination of monocyte subsets in the blood and BAL samples from

### 1502 non-Covid-19 and Covid-19 patients

1503





1505

1506

1507 Peripheral blood from healthy participants (n=12), and asymptomatic-to-mild 1508 (n=15), moderate (n=15), severe (n=35), or critical (n=20) patients, and BAL from Covid-1509 19 (n=10) and non-Covid-19 (n=11) participants were collected and used for the 1510 characterisation of monocyte subpopulations by flow cytometry and t-distributed 1511 stochastic neighbour embedding (t-SNE) analysis. (A) Frequency of CD14<sup>+</sup>HLA-DR<sup>+</sup> cells. (B) t-SNE evaluation of classical (CD14<sup>high</sup>CD16<sup>-</sup>), intermediate (CD14<sup>+</sup>CD16<sup>+</sup>), 1512

1513 and non-classical CD14<sup>low</sup>CD16<sup>+</sup> blood monocytes in Covid-19 patients, categorised 1514 according to disease severity. (C) Colour mapping t-SNE and violin plot showing the 1515 mean fluorescence intensity (MFI) of HLA-DR expression in the circulating monocytes 1516 of Covid-19 subjects. In (D) and (E), samples of BAL from non-Covid-19 and Covid-19 1517 patients were evaluated to determine the frequency of CD14<sup>+</sup>HLA-DR<sup>+</sup> cells and 1518 classical, intermediate, or non-classical monocyte subsets, respectively. Differences 1519 among groups were calculated using the Kruskal-Wallis test with Dunn's multiple 1520 comparison post-test, and the corresponding values are indicated in the figures.

1521 In comparison to healthy participants (Figure S3A, S3B, and 3SC), a significant 1522 reduction was observed in the intermediate monocyte population, as well as in the 1523 expression of HLA-DR molecules in the blood of Covid-19 patients, depending on 1524 disease severity. The diminishment of HLA-DR in monocytes correlated with TNF values 1525 obtained in the blood of patients positive for SARS-CoV-2 (Figure 2P; principal article), 1526 since monocytes with a pro-inflammatory profile are the main producers of this cytokine 1527 <sup>144</sup>. Similarly, reduced intermediate monocytes were found in the BAL of patients positive 1528 for Covid-19 (Figure S3E). Interestingly, these patients also had a significant increase in 1529 the production of IL-8, IL-10, and IL-6 cytokines in the blood and BAL, as shown before 1530 (Figure 2M, 2N, and 2Q and Figure 4A; principal article). The high production of 1531 cytokines, especially IL-6, in patients with Covid-19, has been correlated with a decrease 1532 in the expression of HLA-DR in monocytes, while the therapeutic inhibition of IL-6 re-1533 established the expression of this molecule in those individuals<sup>145</sup>

#### 1534 Figure S4 - Biomarker networks in non-Covid-19 and healthy participants



1535

A network of interactions between lipid mediators, ACh, sCD14, and cytokines in (A) 1536 1537 healthy participants (n=39) and (B) BAL non-Covid-19 participants (n=13). Network layouts of 1538 personalised biomarkers were set up to identify the relevant association in healthy and non-Covid-1539 19 participants. Each connecting line denotes a significant correlation between a pair of markers. 1540 Continuous lines represent positive correlations, while dashed lines represent negative 1541 correlations (p < 0.05). The degree of significance is represented by the thickness of the line. 1542 Correlations were determined using Spearman's test; the values of r and p were used to classify 1543 the connections as weak ( $r \le 0.35$ , p < 0.05), moderate (r = 0.36 - 0.67, p < 0.01), or strong ( $r \ge 0.68$ , 1544 p < 0.001). The absence of a line indicates the non-existence of the relationship. To evaluate the 1545 relationship between levels of lipid mediators, ACh, sCD14, and cytokines in non-Covid-19, a 1546 series of correlation analyses were performed.

1547 When comparing the interactions analysed between the molecules of the healthy and non-Covid-19 groups, we observed that (A) In the blood of healthy individuals, the interactions were 1548 1549 found to occur mainly between cytokines (IL-1β, TNF, IL-8, IL-6, and IL-10) and the lipid 1550 mediator 5-HETE. (B) In thee BAL samples from hospitalised non-Covid-19 patients, lipid 1551 mediators were found to mediate these interactions and influence the clinical outcomes of this 1552 group of patients.

#### 1553 Figure S5 – Treatment of severe and critical SARS-CoV-2-infected patients with



#### 1554 glucocorticoids inhibits ACh release



1556

1557 The production of lipid mediators and the shedding of sCD14 in patients with Covid-19 1558 at the severe and critical stages was not modified by treatment with glucocorticoids (GC). 1559 However, a marked reduction was observed in ACh release. Intersection analysis depicted in 1560 Venn diagrams revealed the number of patients producing AA, 5-HETE, 11-HETE, ACh, or 1561 sCD14, above the control (healthy participants) values, in the absence (A) or presence (B) of GC 1562 therapy. The table shows the number (n) of plasma or BAL samples from Covid-19 patients at 1563 the severe and critical stages of disease, for each mediator. The percentages shown in parentheses 1564 represent the frequency of patients producing the respective mediator for the corresponding 1565 sample number.

1566 The Venn diagrams show the intersections of AA, 5-HETE, 11-HETE, ACh, and sCD14s 1567 in Covid-19 patients at the severe and critical stages of the disease, in both blood and BAL. No 1568 significant changes were observed in the quantification of lipid mediators or sCD14, comparing 1569 patients treated with or without glucocorticoids (Figure S5A and FigureS5B). Interestingly, 1570 critically ill patients treated with glucocorticoids showed a 20% and 65% reduction in the ACh

1571 concentration in both blood and BAL samples, respectively, compared to patients who were not 1572 administered drugs (Figure S5B). While a decrease in free-AA and its metabolites (5-HETE and 1573 11-HETE) has not been reported in the literature, some studies have demonstrated the beneficial 1574 effects of the use of glucocorticoids in other respiratory syndromes, having been found to reduce the production of AA-derived mediators <sup>72,146</sup>. In agreement with our results, there is no evidence 1575 1576 to support corticoid treatment for Covid-19<sup>147</sup>. Data related to the effect of glucocorticoids on 1577 ACh release in viral infections are scarce. However, according to our previous findings on 1578 scorpion envenomation<sup>3</sup>, glucocorticoid treatment should be initiated early after infection to block 1579 the release of lipid mediators, which could lead to the inhibition of premature ACh release. On 1580 the contrary, the late administration of GC could place patients at a point of no return, with early 1581 ACh release impacting vital organs, damaged by the negative impacts of this neurotransmitter 1582 before GC administration. Moreover, it should be considered that, in Covid-19, other unknown

1583 mechanisms may control ACh release, in addition to the COX-2 dependent metabolites.

#### 1584 Figure S6 - Differential expression and profile of genes involved in AA and ACh

### 1585 pathways from SARS-CoV-2 deceased patients

1586



1588

1589 Abbreviations: CVL, Covid-19 low viral load; CVH, Covid-19 high viral load; NCV,

non-Covid-19 viral load 9,50,110,113. 1590

1591 As shown in (A), DEGs were upregulated in CVL versus CVH patients and CVL 1592 versus NCV patients. The transcript expression of cholinergic receptors (muscarinic and 1593 nicotinic) (B) and eicosanoid receptors (C) was normalised in the NCV, CVH, and CVL 1594 groups. CVL patients displayed increased pulmonary levels of expression of genes

- associated with the ACh and AA pathways, encoding for cholinergic receptors, the ACh
- 1596 release cycle, AA metabolism, and eicosanoid receptors, compared to CVH or NCV
- 1597 patients. The expression profile of some genes may favour inflammatory events, such as
- 1598 upregulated cholinergic and eicosanoid receptors (CHRM3, CHRNA3, CHRNA5, and
- 1599 OXER1) and low levels of the anti-inflammatory cholinergic receptor (CHRNA7)
- 1600 <sup>9,50,110,113</sup>.